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MEDICATION ABORTION EXCEPTIONALISM
Greer Donley†
Though state laws dominate the abortion debate, there is
a federal abortion policy that significantly curtails access to
early abortion in all fifty states. The policy, known as a Risk
Evaluation and Mitigation Strategy (REMS), limits the distribution of mifepristone, the only drug approved to terminate a
pregnancy so long as it is within the first ten weeks. Unlike
most drugs, which can be prescribed by licensed healthcare
providers and picked up at most pharmacies, the Food and
Drug Administration only allows certified providers to prescribe mifepristone, and until December 2021, only allowed
those providers to distribute the drug to patients directly, in
person, not through pharmacies. This policy has segregated
abortion care outside of the traditional healthcare setting and
into abortion clinics, which provide ninety-five percent of abortions. This paper is the first to examine the burdens, benefits,
and impacts of the mifepristone REMS. It argues that
mifepristone fails to meet the statutory criteria for a REMS,
and that the FDA’s improper regulation of mifepristone is a
part of a larger history of biased decision-making over sexual
and reproductive health. It concludes by exploring impending
modifications to the mifepristone REMS, what they mean for
the future of early abortion care, and how the FDA can go
further to remove unnecessary barriers to medication abortion.
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† Greer Donley is an Assistant Professor at the University of Pittsburgh Law
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to a large group of interdisciplinary scholars. She would particularly like to thank
Saint Louis University School of Law, which organized the event, and Seema
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State abortion laws have received an enormous amount of
attention in the national discourse and legal scholarship. But
less known is a federal policy that dramatically limits access to
abortion throughout the United States. The policy, created by
the Food and Drug Administration (FDA), has burdened access
to the medication used to induce abortion in the first ten weeks
of pregnancy, mifepristone, through what is known as a Risk

R
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1
Risk Evaluation and Mitigation Strategy (REMS) Single Shared System for
Mifepristone 200MG, U.S. FOOD & DRUG ADMIN., https://www.accessdata.fda.gov/
drugsatfda_docs/rems/Mifepristone_2019_04_11_REMS_Document.pdf [https:/
/perma.cc/C5UE-UV9Q] (last updated Apr. 2019) [hereinafter REMS].
2
Risk Evaluation and Mitigation Strategies (REMS), U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluationand-mitigation-strategies-rems [https://perma.cc/C45E-6U7Y] (last updated
Aug. 8, 2019).
3
See infra Part I.
4
See infra Part II.
5
See Whole Woman’s Health v. Jackson, 141 S. Ct. 2494, 2495 (2021).
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Evaluation and Mitigation Strategy (REMS).1 A REMS subjects
a drug to additional controls that theoretically improve the
drug’s safety profile at the expense of accessibility.2 The
mifepristone REMS has historically been quite stringent—it
dramatically limited access to medication abortion and effectively isolated abortion care outside of traditional medical settings.3 Though the FDA is only supposed to institute a REMS
when it concludes that additional regulation is needed to ensure that a drug’s health benefits outweigh its safety risks,
every medical organization to consider mifepristone’s risk profile has found that the REMS is unnecessary to protect patient
safety.4 In light of this growing criticism, in December 2021,
the FDA removed one of its most onerous restrictions; nevertheless, the agency maintained the mifepristone REMS and
added a new restriction, continuing its exceptional treatment of
the drug.
After the 2020 election, abortion rights activists have been
concerned about the future of their mission. Justice Barrett
was confirmed to fill Justice Ginsburg’s seat only eight days
before the election—a replacement that threatened most of the
rights Justice Ginsburg had championed, perhaps most
acutely, abortion rights. The future of abortion rights has only
become more uncertain since then, with Texas enacting the
harshest abortion ban since before Roe v. Wade and the Supreme Court reconsidering the right to abortion this term in
Dobbs v. Jackson Women’s Health Organization.5 Nevertheless,
the Biden administration has the ability and opportunity to
remove or further loosen the mifepristone REMS, expanding
abortion access throughout much of the country. This Article
explores the rationale for removing the mifepristone REMS and
what impact that decision could have for abortion rights
generally.
Most people have an unchallenged background assumption that abortion occurs outside of the traditional healthcare
setting, typically at an abortion or family planning clinic. That
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RACHEL K. JONES, ELIZABETH WITWER & JENNA JERMAN, ABORTION INCIDENCE
SERVICE AVAILABILITY IN THE UNITED STATES, 2017, at 16 (2019), https://
www.guttmacher.org/sites/default/files/report_pdf/abortion-incidence-serviceavailability-us-2017.pdf [https://perma.cc/Z6CM-BMCD]. As discussed in the
final section of the Article, the COVID-19 pandemic, and the temporary suspension of the mifepristone REMS that resulted from it, has radically disrupted the
provision of abortion care and moved abortion access increasingly online.
7
Some states have their own laws that would limit the distribution of
mifepristone even if the REMS were lifted. See infra subpart IV.B.
8
REMS, supra note 1.
9
See infra Part I.
10
See JONES, WITWER & JERMAN, supra note 6, at 3.
11
Letter from FDA to Maureen G. Phipps, MD, MPH & FACOG, CEO of Am.
Coll. of Obstetricians and Gynecologists, and William Grobman, MD & MBA,
President of Soc’y for Maternal-Fetal Med. (Apr. 12, 2021) (on file with the ACLU),
https://www.aclu.org/letter/fda-response-acog-april-2021 [https://perma.cc/
3JZM-XD2R].
AND
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is because 95% of abortions—including abortions that are
completed with a simple medication regimen—have historically
been provided by those clinics.6 There is no reason, however,
for medication abortion to be limited to any physical space. So
long as abortion patients are within the first ten weeks of their
pregnancies, they should simply be able to make an appointment with a general practitioner or OBGYN, obtain a prescription for medication abortion, pick up the medications at their
regular pharmacy, and end their pregnancy in the privacy of
their home. The primary obstacle blocking this scenario from
coming to fruition in more than half the country is the FDA’s
REMS.7
The mifepristone REMS created distribution limitations
that, in effect, isolated early abortion care to clinics. Until December 2021, the REMS barred pharmacies from distributing
mifepristone and required patients to pick up the drug in person from a “certified prescriber” at a clinic, medical office, or
hospital.8 The logistical burdens associated with certification
and distribution ensured that the vast majority of providers
who became certified were abortion providers working at abortion and family planning clinics.9 And given that clinics are few
and far between in most southern and midwestern states, the
REMS effectively required women to travel far distances—
sometimes hundreds of miles—to simply pick up a prescription.10 It also prevented women from obtaining the prescription through telehealth, which became an urgent necessity in
the COVID-19 pandemic.
Quickly after taking office, the Biden administration used
its discretion to suspend the in-person dispensing requirement
associated with the mifepristone REMS11—an action the
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Trump administration refused to take, and the Supreme Court
found was not legally required.12 In the months after the suspension took effect, abortion care started to change dramatically in many states, including the creation of virtual clinics,
which provide medication abortions entirely through
telehealth.13 Remote abortion care is cheaper, more convenient, and allows patients to avoid the harassment associated
with clinics. On December 16, 2021, the FDA permanently
removed the in-person dispensing requirement, ensuring that
these important changes could become permanent.14 But the
agency stopped short of removing the REMS entirely, keeping
the certified provider requirement and patient agreement form,
and adding a requirement that any pharmacy dispensing the
drug also become certified.15
This Article starts with background on medication abortion, including its risks and benefits, the FDA’s history regulating it, and the negative impact of that regulation on abortion
access. Part II then examines whether the burdens associated
with the REMS are offset by any health benefit, as the statute
requires. It concludes, as has every major medical organization to examine the issue, that there are no demonstrated medical benefits to the REMS. Medication abortion is both safe and
effective without limits on distribution. Though there are real
risks to mifepristone—as there are for every drug—there is no
reason that a physician or pharmacist could not ensure that
patients are informed of the risks and how to manage them. As
a result, the Part concludes that mifepristone failed to meet the
statutory criteria for a REMS.
In Part III, the Article describes how the FDA’s mifepristone
REMS is a part of a larger pattern of gender bias in the FDA’s
decision making. The Part traces a series of agency failures to
protect women’s health, especially reproductive and sexual
health, over the course of decades. This Part concludes that
the FDA has a history of placing political concerns over its
scientific mission when it comes to issues concerning female
sexuality and reproduction.
Finally, Part IV explores legal and political avenues for invalidating, removing, or loosening the mifepristone REMS, as
12
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FDA v. ACOG, 141 S. Ct. 578, 578 (2021).
See infra subpart IV.B.
14
Letter to Donna Harrison from the Food & Drug Admin. (Dec. 16, 2021) at
6-7, https://www.regulations.gov/document/FDA-2019-P-1534-0016 [https://
perma.cc/ED3T-SUJM] [hereinafter FDA Letter].
15
Id.
13
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the medical evidence supports. The Part then pivots to a discussion of how a removal of the REMS could reshape early
abortion care in the United States, integrating it into the traditional healthcare system and making it more accessible than
ever before. But perhaps the largest impact of loosening the
REMS would be to accelerate the polarization in abortion access across state lines. Nineteen states have their own laws
limiting the distribution of medication abortion, and more
states might erect similar barriers.16 In these states, the innovations in early abortion care, like virtual abortion clinics,
would remain unavailable. If Roe v. Wade is further limited or
overturned in the coming years, this disparity will grow
again.17 Women living in liberal states will continue to experience the benefits of remote abortion access, while women in
conservative states could lose legal access to in-state abortion
care altogether. Since SB 8 took effect in Texas—a law that
has, in effect, ended legal abortion starting roughly two weeks
after a woman’s missed period—this polarization is already on
display.18 Nevertheless, Texas also proves that modifications
to the REMS will facilitate abortion access in these antiabortion
states by making it easier for women to get medication abortion
from neighboring states.19

06/09/2022 09:20:03
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16
Medication Abortion, GUTTMACHER INST., https://www.guttmacher.org/
state-policy/explore/medication-abortion [https://perma.cc/4JRF-NNT5] (last
updated Nov. 1, 2021).
17
410 U.S. 113 (1973).
18
See Greer Donley, David S. Cohen & Rachel Rebouché, The Messy Post-Roe
Legal Future Awaiting America, ATLANTIC (Sept. 27, 2021), https://
www.theatlantic.com/ideas/archive/2021/09/after-roe-legal-mess-future-abortion-rights/620134/ [https://perma.cc/U53S-7X8P].
19
Already, in Texas, virtual clinics are working to serve Texas women in
neighboring states where remote abortion is legal, like Colorado and Nevada.
Carey Goldberg & Catarina Saraiva, Texas Ban May Spur Tele-Abortions: Virtual
Visits, Then Pills, BLOOMBERG (Sept. 4, 2021), https://www.bloomberg.com/news/
articles/2021-09-04/texas-ban-may-spur-tele-abortions-virtual-visits-then-pills
[https://perma.cc/8BYS-K62V]. This will help patients obtain remote abortion
care by simply crossing the border, instead of also needing to travel to an abortion
clinic in that state. It will also help reduce pressure on the providers doing
surgical abortion procedures, who have seen an influx of Texan patients. As
argued in subpart IV.B, experts also expect to see an increase in illegal selfmanaged abortion for women who cannot travel, which appears to be already
happening in Texas as well. Tanya Basu, Activists Are Helping Texans Get Access
to Abortion Pills Online, MIT T ECH. REV. (Sept. 15, 2021), https://
www.technologyreview.com/2021/09/15/1035790/abortion-pills-online-texassb8/ [https://perma.cc/4VV9-C785].
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I
THE STIFLED PROMISE OF MEDICATION ABORTION
Mifepristone is a drug that, when used in combination with
misoprostol, terminates a pregnancy. Mifepristone was originally sold exclusively under the brand name Mifeprex, but the
FDA also approved a generic version of the drug in 2019.20
Mifepristone works by blocking the hormone progesterone,
which is necessary for a pregnancy to continue.21 In particular, when progesterone is blocked during pregnancy, it alters
the lining of the uterus and causes disruption to the decidua
(which later becomes the placenta).22 By thinning the uterine
lining, mifepristone detaches the gestational sac from the
uterus and stops its growth.23 It can also cause the cervix to
soften and dilate, which can help express the pregnancy.24
Mifepristone, however, is not always sufficient to end a
pregnancy on its own, which is why it is used in combination
with a second drug, misoprostol. Misoprostol causes contractions that help expel the pregnancy.25 It is typically taken
24–48 hours after mifepristone.26 Unlike mifepristone, which
is the only drug approved as an abortifacient, misoprostol was
originally approved to prevent stomach ulcers after the use of
certain anti-inflammatory drugs.27 However, it has been used
off label28 for a variety of obstetric uses—including to induce
labor or evacuate a pregnancy after an incomplete or missed

06/09/2022 09:20:03
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20
This Article uses the term “mifepristone” to refer to both the generic and
brand name drug. Questions and Answers on Mifeprex, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-andproviders/questions-and-answers-mifeprex [https://perma.cc/F46V-34CP] (last
updated Apr. 13, 2021). The agency consolidated both products under a single
REMS, but otherwise made no substantive changes to the REMS protocol. Id.
21
Irving M. Spitz & C.W. Bardin, Mifepristone (RU 486I) – A Modulator of
Progestin and Glucocorticoid Action, 329 NEW ENG. J. MED. 404, 405 (1993).
22
Id.
23
Medical Abortion, MAYO CLINIC (May 14, 2020), https://www.mayoclinic.org
/tests-procedures/medical-abortion/about/pac-20394687 [https://perma.cc/
Z284-2M7H].
24
Spitz & Bardin, supra note 21, at 405.
25
Medical Abortion, supra note 23.
26
The Availability and Use of Medication Abortion, KAISER FAM. FOUND.
(June 16, 2021), https://www.kff.org/womens-health-policy/fact-sheet/theavailability-and-use-of-medication-abortion/ [https://perma.cc/NN8S-R4DV].
27
Rebecca Allen & Barbara M. O’Brien, Uses of Misoprostol in Obstetrics and
Gynecology, 2 REVS. OBSTETRICS & GYNECOLOGY 159, 159 (2009).
28
Off-label use refers to when a physician prescribes medication for a use
that was not approved by the FDA. Understanding Unapproved Use of Approved
Drugs “Off Label,” U.S. FOOD & DRUG ADMIN., https://www.fda.gov/patients/
learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label [https://perma.cc/DL5G-ZMWV] (last updated Feb. 5, 2018).
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miscarriage.29 Perhaps due to its variety of other uses outside
of the abortion context, misoprostol has not been subject to the
same controversy or regulatory limitations on its distribution
despite similar side effects and risks. As a result, women can
obtain misoprostol as any other drug, with a prescription from
their pharmacy.30
Though there are other drug regimens that can effectively
terminate a pregnancy, 97% of medication abortions in the
United States use the FDA-approved combination of mifepristone and misoprostol.31 With more than twenty years of safety
data, there is ample evidence that mifepristone is both safe and
effective. In 2018, the Government Accountability Office (GAO)
published a report on mifepristone; it found that from September 2000 to June 2017, 3.2-million women used mifepristone
to end a pregnancy.32 Of those women, only 4,200 reported
adverse events, including twenty deaths—some of which were
later found to be unrelated to the medication.33 The fatality
rate was calculated at 0.0006%.34 “In contrast, the background risk of pregnancy-related death among pregnant women in the United States who do not have abortions and
instead proceed to live birth is approximately 0.009%, which is
14 times higher.”35 The rates of serious adverse events like
infection requiring hospitalization are also low, ranging from
0.01 to 0.7%, and are almost always treatable without longterm issues.36 As for efficacy, the drug’s current label reports

06/09/2022 09:20:03
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29
Allen & O’Brien, supra note 27, at 164. Studies have recently shown that a
combination of mifepristone and misoprostol would be more effective at treating
an incomplete miscarriage, but the regulatory limits on mifepristone have made
that protocol more difficult to implement. Courtney A. Schreiber et al., Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss, 378 NEW
ENG. J. MED. 2161, 2161 (2018).
30
Pharmacists can, however, invoke conscience laws to avoid dispensing
misoprostol.
31
Rachel K. Jones & Jenna Jerman, Abortion Incidence and Service Availability in the United States, 2014, 49 PERSPS. ON SEXUAL & REPROD. HEALTH 1, 6 (2017),
https://www.guttmacher.org/sites/default/files/article_files/abortion-incidence-us.pdf [https://perma.cc/6XZL-X8NL].
32
GOV’T ACCOUNTABILITY OFF., GAO-18-292, FOOD AND DRUG ADMINISTRATION:
INFORMATION OF MIFEPREX LABELING CHANGES AND ONGOING MONITORING EFFORTS 21
(2018), https://www.gao.gov/assets/700/690914.pdf [https://perma.cc/9MTNEDK7] [hereinafter GAO-18-292].
33
Id.
34
Id.
35
Mifeprex REMS Study Grp., Sixteen Years of Overregulation: Time to Unburden Mifeprex, 376 NEW ENG. J. MED. 790, 791 (2017) [hereinafter Mifeprex REMS
Study Group].
36
Id.
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that it is over 96% effective at ending a pregnancy.37 For the
remaining cases, an additional dose of misoprostol will frequently expel the remaining tissue.38 In roughly 1% of cases, a
surgical procedure is required.39
The possibility of abortion by medication was enormously
controversial from the moment it first entered the public debate: “[a]lmost no pharmaceutical product has captured the
public imagination with the force of mifepristone.”40
Initially, predictions were both dire and ecstatic: women
would run rampant, having more abortions than ever, boyfriends would slip mifepristone into their girlfriends’ tea,
abortion would become simple and easy, women would have
access to abortion without any medical interface and the
politics of abortion would soften.41

Thus far, none of these predictions have come to pass, including the drug’s promise to dramatically increase the accessibility
of abortion in the United States (though that might be changing).42 In 2017, roughly forty percent of U.S. abortions are now
completed with medication,43 but accessing the drugs has not
been easy.44 Some have decried that mifepristone is, and must
remain, “the moral property of women,” but the potential for
any woman45 or pregnant person in America to access the medication at her local pharmacy with a prescription from her regular provider—as they do with other medications—is not yet a
reality in the United States.46 As explained below, this is
largely due to an FDA policy that limits the distribution of
mifepristone.

R
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37
Mifeprex Label, 13, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf [https://perma.cc/PZ9U-NN6B]; Older studies using an outdated dosing regimen demonstrated a lower efficacy. See GAO-18-292,
supra note 32, at 13.
38
GAO-18-292, supra note 32, at 14.
39
Mifeprex Label, supra note 37, at 13.
40
Beverly Winikoff & Carolyn Westhoff, Fifteen Years: Looking Back and
Looking Forward, 92 CONTRACEPTION 177, 178 (2015).
41
Id.
42
See The Availability and Use of Medication Abortion, supra note 26, at 8.
43
Id. As noted below, medication abortion for the first time became the majority of all abortions in 2020 (54%).
44
See infra subpart I.C.
45
Not every person capable of becoming pregnant identifies as a woman. As
a result, I attempt to primarily use gender neutral language. There are times,
however, where I use gendered language because gender is relevant, or the language is less clunky. But in those instances, the arguments apply with equal
force to all people with uteruses, however they identify.
46
Winikoff & Westhoff, supra note 40, at 178 (quoting Claude Evin, the thenFrench Minister of Health).
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A. Creation of the Drug
Researchers conceived of the idea for mifepristone after
studies of hormone-based contraception; once scientists understood the role that progesterone plays in pregnancy, they
began to theorize that anti-progestins could also interrupt an
embryo’s implantation in the uterus.47 The pharmaceutical
company, Roussel Uclaf, eventually created mifepristone and
named it RU-486.48
In 1982, the first clinical trial for mifepristone began in
Geneva.49 Nine out of the eleven women who participated in
the study successfully terminated their pregnancies.50 Additional studies were conducted to expand this research, including the first U.S. study in 1983 involving 300 research subjects
in California.51 In 1988, after many successful clinical trials in
France,52 the French government approved mifepristone (still
then known as RU-486) for use as an abortifacient.53 The decision was highly controversial, and Roussel Uclaf even stopped
selling the drug for a few days after anti-abortion organizations
threatened the company.54 Nevertheless, the drug reentered
the market after the French government successfully intervened.55 China also approved mifepristone as an abortifacient
in 1988.56 Britain and Sweden followed within a few years,57
and the entire EU had access by 1999.58
Roussel Uclaf was hesitant to apply for new drug approval
in the United States, fearing boycotts and lawsuits.59 The risks
were especially undesirable in the Bush administration, which
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47
Randall K. O’Bannon, The Introduction and Use of the Abortifacient
Mifepristone (RU-486) in the United States, 24 ASS’N FOR INTERDISC. RSCH. IN VALUES
AND SOCIAL CHANGES: RSCH. BULLETIN (2012).
48
Carolina J. Abboud, The Development of Mifepristone for Use in Medication
Abortions, EMBRYO PROJECT (Aug. 7, 2017), https://embryo.asu.edu/pages/development-mifepristone-use-medication-abortions [https://perma.cc/7DHDJHG3].
49
Id. at 1.
50
Id.
51
See THE CASE FOR ANTIPROGESTINS: A REPORT OF THE REPRODUCTIVE HEALTH
TECHNOLOGIES PROJECT, REPROD. HEALTH TECH. PROJECT 5–6 (1992).
52
Rebecca K. Kramnick, RU 486 and the Politics of Drug Regulation in the
United States and France, 25 CORNELL INT’L L.J. 677, 686 (1992).
53
THE CASE FOR ANTIPROGESTINS, supra note 51, at 7.
54
JUDITH A. JOHNSON, CONGRESSIONAL RESEARCH SERVICE, ABORTION: TERMINATION OF EARLY PREGNANCY WITH RU-486 (MIFEPRISTONE) 1 (2001).
55
Id. at 1–2.
56
Id. at 1.
57
Winikoff & Westhoff, supra note 40, at 177.
58
Id.
59
Lars Noah, A Miscarriage in the Drug Approval Process?: Mifepristone Embroils the FDA in Abortion Politics, 36 WAKE FOREST L. REV. 571, 579 (2001).
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had already tried to ban the importation of mifepristone for
personal use, as described in Part III below.60 But once President Clinton entered office, his administration took the unusual step of actively recruiting the company to seek FDA
approval, even helping the reluctant sponsor to negotiate licenses so that its brand would not be affected in the United
States.61 In 1994, “after lengthy negotiations” with the Clinton
administration,62 Roussel Uclaf “donated the rights to sell
mifepristone in the United States to the Population Council, a
large nonprofit group in New York City that conducts international research on reproductive health.”63 The Population
Council searched for large pharmaceutical companies to develop the drug, but was unsuccessful; it eventually licensed the
rights to produce and distribute mifepristone, sold under the
brand name Mifeprex, to Danco Laboratories, LLC (“Danco”) in
1997.64
B. Federal Regulation in the United States

60

See infra Part III; Benten v. Kessler, 799 F. Supp. 281, 285–86 (E.D.N.Y.

1992).
61
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Noah, supra note 59, at 578–79.
Id. at 579.
63
Melody Petersen, Abortion Pill Distributor Energized by New Mission, N.Y.
TIMES (Sept. 30, 2000), https://www.nytimes.com/2000/09/30/us/abortionpill-distributor-energized-by-new-mission.html [https://perma.cc/MB6W-RGPL].
64
Id.
65
Greer Donley, Regulation of Encapsulated Placenta, 86 TENN. L. REV. 225,
242 (2019).
66
The original NDA was submitted by the Population Council; but Danco
took over during the NDA process, and for ease of reference, this Article refers to
Danco as the sponsor. U.S. GOV’T ACCOUNTABILITY OFF., GAO-08-751, APPROVAL AND
OVERSIGHT OF THE DRUG MIFEPREX 4 n.12 (2008), https://www.gao.gov/assets/
280/279424.pdf [https://perma.cc/3MMJ-ESDD] [hereinafter GAO-08-751].
67
Id. at 5–6.
68
Id.
62
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In the United States, drug regulation is largely governed by
the Food and Drug Administration (FDA). Drugs cannot be
sold or distributed through interstate commerce unless they
receive new drug approval from the FDA.65 In 1996, mifepristone’s sponsor, Danco, submitted a new drug application (NDA)
for FDA approval.66 Later that year, the FDA sent a letter to
Danco indicating that although the available evidence from
abroad suggested that the drug was safe and effective, it could
not approve the drug until it had final data from a clinical trial
in the United States.67 The FDA also requested that the sponsor submit a plan on how to restrict the drug’s distribution.68
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Id. at 19.
Noah, supra note 59, at 583.
71
Id.
72
Id. at 584; GAO-08-751, supra note 66, at 5.
73
GAO-08-751, supra note 66, at 5.
74
Memorandum entitled NDA 20-687 Mifeprex (mifepristone) Population
Council, at 1 (Sept. 28, 2000), http://wayback.archive-it.org/7993/
20170113112743/http://www.fda.gov/downloads/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm111366.pdf
[https://perma.cc/FZ2Q-8S6R] [hereinafter Mifepristone Memorandum].
75
Id. at 6, 8.
76
GAO-08-751, supra note 66, at 6. The GAO reviewed this determination in
2008 and found it appropriate. Id. at 25–28.
77
Mifepristone Memorandum, supra note 74, at 6. The initial restrictions
included many other provisions related to informed consent, shipping controls,
and additional research. Id. at 3–8.
70
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Three years later, in 1999, Danco responded to the FDA’s
letter and included data from a U.S. clinical trial showing that
the drug was safe and effective.69 By this time, the Clinton
administration’s previous enthusiasm to approve mifepristone
had faded as President Clinton sought to rehabilitate his image
after his cheating scandal.70 And as Republicans now had control of the Senate, they were able to hold up the confirmation of
a new FDA Commissioner for two years, only confirming Jane
Henney “after receiving assurances that Dr. Henney would not
actively facilitate final approval of mifepristone.”71 Nevertheless, after reviewing the new information Danco submitted, the
FDA agreed that the drug was safe and effective, but “suggested
a variety of unusual distribution restrictions such as making
the drug available only through physicians who performed surgical abortions [who] would agree to register with the manufacturer.”72 The FDA finally approved mifepristone in 2000 after
reaching an agreement with the sponsor on the limited distribution plan, labeling, and manufacturing processes.73
The FDA’s initial approval of mifepristone was through the
first forty-nine days of pregnancy.74 It used the agency’s Subpart H authority to restrict mifepristone’s distribution; Subpart
H allows distribution restrictions for drugs treating serious or
life-threatening illnesses.75 The sponsor objected to this classification, but the “FDA concluded that termination of an unwanted pregnancy is a serious condition and that the drug can
allow patients to avoid a surgical procedure.”76 The FDA’s primary restrictions were to prohibit pharmacies from distributing the drug—only qualified physicians could do so.77 A
physician was qualified only if she could “assess the duration
of pregnancy accurately,” “diagnose ectopic pregnancies,” “provide surgical intervention” or had “plans to provide such care
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through other qualified physicians” in the case of
complications.78
At the time, physicians could only distribute mifepristone
in person and were required to supervise the administration of
the drug—i.e., the patient was not allowed to take the drug at
home.79 Patients were also required to return to the office a few
days later to take the second drug in the regimen, misoprostol,
in person.80 Finally, the drug also was given a black box warning—the most aggressive warning the FDA can require.81
Black box warnings are typically reserved for drugs that can
cause serious injury or death.82
The FDA’s distribution restrictions were seen as problematic from the outset. In 2001, FDA law scholar, Lars Noah,
wrote:
This degree of oversight resembles some of the restrictions
imposed on Schedule II controlled substances such as methadone, but no one has suggested that mifepristone qualifies
as a narcotic subject to the Controlled Substances Act, and
nothing in the FDA’s enabling statute explicitly authorized
the imposition of such controls on access to the drug.83
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Nevertheless, the restrictions persisted and were recrafted into
a REMS once Congress passed the Food and Drug Administration Amendments Act, which created the REMS program in
2007.84 This statute created the REMS system, which it described as “a drug safety program that the [FDA] can require for
certain medications with serious safety concerns.”85 The statute requires the FDA to issue a REMS if it “determines that [it]
is necessary to ensure that the benefits of the drug outweigh
78
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Id. at 6.
Id. at 8.
80
Id. at 2–3.
81
A GUIDE TO DRUG SAFETY TERMS AT FDA, FOOD & DRUG ADMIN. (2012), https:/
/www.fda.gov/media/74382/download#:~:text=this%20type%20of%20warning
%20is,serious%20or%20life%2Dthreatening%20risks.&text=NOVEMBER
%202012-,cause%20disability%2C%20are%20life%2Dthreatening%2C%20result
%20in%20hospitalization%20or,death%2C%20or%20are%20birth%20defects
[https://perma.cc/7HDN-5NB7].
82
The current black box warning notes, among other things, that “[s]erious
and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions.” HIGHLIGHTS OF PRESCRIBING INFORMATION,
FOOD & DRUG ADMIN. 1 (2016), https://www.accessdata.fda.gov/drug
satfda_docs/label/2016/020687s020lbl.pdf [https://perma.cc/FCD5-CXGG].
83
Noah, supra note 59, at 584 (citations omitted).
84
FDA’s REMS authority was a part of the Food and Drug Administration
Amendments Act, which was passed in 2007. 21 U.S.C. § 355-1.
85
Risk Evaluation and Mitigation Strategies (REMS), supra note 2.
79
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the risks of the drug.”86 The statute also allows the FDA to use
its deeming authority to institute a REMS for a previously approved drug if the drug was already on the market with distribution limitations.87 Given the restrictions that the FDA had
already placed on mifepristone, the FDA used its deeming authority to require a REMS on the drug in 2008.88
A REMS does not always create limitations on drug distribution; it could simply involve a communication plan, including a medication guide for patients or risk disclosures from the
manufacturer to the provider.89 When the FDA concludes that
those basic REMS requirements are insufficient to protect patient safety, it can issue what is known as Elements to Assure
Safe Use (ETASU)—a more stringent REMS90 that may include
limits on distribution, including restrictions on who can prescribe the drug and under what conditions.91 The FDA’s
mifepristone REMS includes ETASU.92 Though there are only
sixty-one REMS programs93 covering less than 5% of all FDAapproved drugs,94 the vast majority (90%) also include
ETASU.95
86

21 U.S.C. § 355-1(a)(1).
See Questions and Answers on the Federal Register Notice on Drugs and
Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/regulatory-information/foodand-drug-administration-amendments-act-fdaaa-2007/questions-and-answersfederal-register-notice-drugs-and-biological-products-deemed-have-risk [https:/
/perma.cc/2KXT-HJBK] (last updated March 28, 2018).
88
Notice, 73 Fed. Reg. 16313, 16313 (Mar. 27, 2008), https://
www.federalregister.gov/documents/2008/03/27/E8-6201/identification-ofdrug-and-biological-products-deemed-to-have-risk-evaluation-and-mitigation
[https://perma.cc/W9DP-ZHWW]. In response, Danco submitted a supplemental
new drug application (sNDA) proposing a REMS that would satisfy the agency,
which the FDA accepted. Letter from Dep’t of Health & Hum. Servs. to Danco
Laboratories, LLC (June 8, 2011), https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020687s014ltr.pdf [https://perma.cc/WL94QVBR].
89
What’s in a REMS?, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/
drugs/risk-evaluation-and-mitigation-strategies-rems/whats-rems [https://
perma.cc/U4SE-ESPQ] (last updated Jan. 26, 2018).
90
The Availability and Use of Medication Abortion, supra note 26.
91
Food and Drug Administration Amendments Act of 2007, Pub. L. No. 11085, 121 Stat. 823.
92
Mifeprex REMS Study Group, supra note 35, at 790.
93
Approved Risk Evaluation and Mitigation Strategies (REMS), U.S. FOOD &
DRUG ADMIN., https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?
event=RemsData.page [https://perma.cc/4JZ5-6X7W] (last visited May 30,
2021).
94
See Mifeprex REMS Study Group, supra note 35, at 790 (identifying that
there were “1750 prescription drug and therapeutic biologic active ingredients
that [had] been approved by FDA and marketed in the United States” as of February 2017).
95
Approved Risk Evaluation and Mitigation Strategies (REMS), supra note 93.
87
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In May 2015, mifepristone’s sponsor submitted a Supplemental New Drug Application (sNDA), which proposed several
changes to the administration of the drug.96 These proposals
included, among other things, “changing the dosing regimen,
increasing the gestational age limit up to which [mifepristone]
can be taken, and eliminating the requirement that the dose of
misoprostol be administered in a medical facility.”97 In the
course of its review, the FDA also received multiple letters from
academics and professional organizations requesting that the
REMS be modified or eliminated.98 In its review of the sNDA,
the FDA concluded that “no new safety concerns have arisen in
recent years, and that the known serious risks occur rarely.”99
It also found that “[g]iven that the numbers of . . . adverse
events appear to be stable or decreased over time, it is likely
that . . . serious adverse events will remain acceptably low.”100
As a result, in 2016, the agency approved the sNDA.101
The modified approval updated the drug’s labeling and REMS
in the following ways:

Nevertheless, the mifepristone REMS and ETASU still required
that (1) only certified healthcare providers104 prescribe the
96
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GAO-18-292, supra note 32, at 1.
Id. at 2.
98
Joint Stipulation of Facts at 11–12, Chelius v. Azar, No. 1:17-cv-00493JAO-RT (D. Haw. Nov. 27, 2019).
99
CTR. FOR DRUG EVALUATION & RSCH., FDA, MEDICAL REVIEW 8 (2016), https://
www.accessdata.fda.gov/drugsatfda_docs/nda/2016/
020687Orig1s020MedR.pdf [https://perma.cc/XT3Q-P6KB].
100
Id. at 47.
101
GAO-18-292, supra note 32, at 6.
102
Id. at 7–8.
103
Id.
104
Only providers that can (a) “assess the duration of pregnancy accurately”
(b) “diagnose ectopic pregnancies” and (c) “provide surgical intervention” or “have
97
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• It extended the gestational age for which the medication
was approved for use (from 49 days to 70 days since a
woman’s last missed period);
• It modified the dose regimen for mifepristone and misoprostol based on research showing improved safety and
efficacy with an altered dose;
• It allowed providers who are not physicians to become
certified to prescribe mifepristone; and
• It removed language requiring the drug to be taken (not
just dispensed) in a healthcare facility.102 The last requirement allowed women to only travel to a clinic once,
where they could pick up the entire medication regimen
and take it at home instead of traveling to the clinic multiple times and taking the drugs at the facility.103
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made plans to provide such care through others” are eligible for certification.
REMS, supra note 1.
105
Id.
106
Mifeprex (mifepristone) Information, Food & Drug Admin., (last updated
Dec. 16, 2021), https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information [https://
perma.cc/SH6R-SP66] (“The revised REMS document and materials will be available within one day after approval on the FDA website,” which has not yet
occurred).
107
Id.
108
See FDA Letter, supra note 14, at 25-38.
109
Id. at 6-7.
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drug, (2) the drug be dispensed in certain healthcare settings,
and (3) patients receive additional counseling and sign a Patient Agreement Form.105
In December 2021, as this Article was coming to press, the
FDA announced an additional change to the mifepristone
REMS, the details of which will be ironed out over the coming
months with the drug’s sponsor.106 The FDA removed the requirement that mifepristone be dispensed in person at a
healthcare facility (known as the in-person dispensing requirement) and allowed pharmacies to prescribe it for the first
time.107 This decision was in response to the mounting evidence that medication abortion can be safely and effectively
prescribed without in-person care—data that surged during
the COVID-19 pandemic when the in-person dispensing requirement was temporarily suspended by court order.108 As
described below, this temporary suspension transformed abortion care in the thirty-one states that did not have their own
laws requiring in-person dispensation. Though the FDA decided to make these changes permanent in December, it otherwise maintained the REMS requirements that providers
become certified to prescribe the drug and that patients be
given extra informed consent; it also added a new requirement—that pharmacies dispensing mifepristone become certified.109 As explored throughout this Article, these burdens are
unnecessary and continue to impede access to early abortion
care.
The following section describes how the FDA’s history in
regulating mifepristone has significantly reduced access to
medication abortion and isolated abortion care outside of the
traditional healthcare setting, perpetuating abortion stigma.
Though some of these effects may start to change with the
FDA’s most recent modification of the REMS, its continued
over-regulation of the drug perpetuates abortion
exceptionalism.
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C. How the FDA’s Regulation of Mifepristone has Harmed
Abortion Access
The mifepristone REMS has serious implications for abortion access. First, the certified provider requirement makes it
difficult for abortion to occur in traditional healthcare settings—within the purview of any Primary Care Physician (PCP)
or Gynecologist—and has instead kept it segregated to abortion
and family planning clinics. Isolating abortion care to clinics
creates unnecessary stigma and logistical barriers. These barriers were especially pronounced in the era of the in-person
dispensing requirement, where abortion patients were required
to travel to clinics to pick up their prescription, even though
clinics are few and far between in many states. The FDA’s new
pharmacy certification requirement similarly prevents medication abortion from being treated like regular healthcare. Second, until very recently, the REMS prevented a pure model of
telemedicine abortion from coming to fruition. In fact, it was
only due to the efforts of researchers during the COVID-19
pandemic, who meticulously documented the safety and efficacy of remote abortion provision when a court temporarily
suspended the in-person dispensing requirement, that the FDA
decided to lift it.110 Though the mifepristone REMS is not the
only factor limiting early abortion access—state abortion laws
also play an important role—the REMS is a major barrier that
must be addressed in order to see significant improvements in
access.
43781-crn_107-3 Sheet No. 10 Side A

1. Segregating Abortion Care Outside of the Traditional
Healthcare Setting
The REMS keeps abortion separate from traditional healthcare by making it difficult or impossible for patients to obtain
mifepristone through their regular pharmacy after an appointment with their regular provider.111 It is true that OBGYNs and
PCPs could apply for certification to dispense mifepristone,112
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110
The FDA refused to suspend the mifepristone REMS during the pandemic,
as it has done for other medications. See U.S. DEP’T OF HEALTH & HUM. SERVS.,
FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RSCH., CTR. FOR BIOLOGICS
EVALUATION & RSCH., POLICY FOR CERTAIN REMS REQUIREMENTS DURING THE COVID19 PUBLIC HEALTH EMERGENCY: GUIDANCE FOR INDUSTRY AND HEALTH CARE PROFESSIONALS 7 n.13 (2020), https://www.fda.gov/media/136317/download [https://
perma.cc/3JUP-T3AV] (suspending multiple REMS for public health reasons, but
leaving in-person dispending requirements in place); FDA v. ACOG, 141 S.Ct.
578, 579 (2021) (Sotomayor, J., dissenting) (noting that mifepristone was subject
to disparate treatment by the agency).
111
See REMS, supra note 1.
112
Almost all physicians are qualified to seek certification. See id.
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113
See Jones & Jerman, supra note, at 6 (noting the lack of physician offices
that provide abortion care).
114
See REMS, supra note 1.
115
The Opt-Out Option, ASS’N FOR PSYCH. SCI. (Sept. 13, 2013), https://
www.psychologicalscience.org/news/minds-business/the-opt-out-option.html
[https://perma.cc/S4DX-RUGK]; Alpha’s Path, Opt-in vs. Opt-out Psychology, MEDIUM (Apr. 25, 2019), https://medium.com/@alphaspath/opt-in-vs-opt-out-psychology-61b974e39ee2 [https://perma.cc/CQD8-SW8N].
116
NAF Releases 2019 Violence & Disruption Statistics, Nat. Abortion Fed.,
(July 30, 2020), https://prochoice.org/naf-releases-2019-violence-disruptionstatistics/ [https://perma.cc/L5ZX-GXH2].
117
Id.
118
Mifeprex REMS Study Group, supra note 35, at 792 (“[T]he expense and
hassle of maintaining drug inventories as well as reluctance to be included on a
list of certified abortion providers—understandable, given the long history of harassment and violence—may discourage some otherwise willing clinicians from
offering medical abortion at all.”).
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and would likely obtain certification if they tried, but the practical barriers may be as effective as a prohibition.113 Unlike
most drugs, where physicians are granted the power to prescribe noncontrolled substances through their medical license,
doctors must affirmatively seek certification to prescribe
mifepristone, a noncontrolled substance.114 Research from
other settings confirms the psychological reality that simply
requiring an affirmative opt-in can discourage behavior.115
This makes sense: opting in requires providers to commit their
time and energy to filling out the certification paperwork.
But opting into prescribing mifepristone also comes with
unique risks to providers that make it even less likely they
would choose to commit the time and resources in applying for
certification. Abortion providers have long faced stigma, harassment, and violence. In 2019, ninety-two abortion providers
experienced death threats; 1,507 experienced trespassing; and
3,123 experienced hate mail or harassing phone calls.116
There have also been eleven murders and six attempted
murders of abortion providers since 1977.117 Certification creates a list of providers who offer abortion care. And though the
drug manufacturers presumably work hard to keep that list
confidential, doctors reasonably worry that their certification
as a mifepristone prescriber could get leaked, subjecting them
to this harassment or violence.118 Some doctors might be willing to provide abortions, but are hesitant to affirmatively identify as an abortion provider given the risks that come with that
designation. For this reason, becoming certified to prescribe
mifepristone is categorically different than seeking certification
to prescribe less stigmatized drugs that are subjected to a simi-
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lar ETASU—that certification process would be less discouraging because it does not also come with these unique risks.119
Moreover, before December 16, 2021, the burdens of certification were perpetuated by the in-person dispensing requirement, which forced providers to also dispense the drug
themselves instead of relying on pharmacies. This created logistical barriers that were difficult to overcome even if providers
were willing to face the hassle and anxieties associated with
certification:
Physicians lack the setup, time and training to manage drug
inventory, including maintaining stock and ensuring that expired medicines are not released. Few doctors are likely to be
willing to stock this expensive medication, reported by the
manufacturer to cost $300 per dose.120 Physicians’ offices
are not usually engaged in retail sales and may not have the
infrastructure to sell a medication, if sales are needed to
dispense it.121

In other words, because most physicians did not have the capability or infrastructure to sell and dispense medication, even
if they became certified, they would not be able to dispense it
themselves, as the REMS required.122
Forcing certified providers to dispense the medication
themselves also imposed financial risks—physicians would
have to buy the medication themselves and then eat the cost if
the drug expired before a woman requested it.123 Predicting
demand would be especially difficult given that many providers
may not feel comfortable advertising that they offer this service,
so even if they were certified to prescribe mifepristone and had
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119
For instance, thalidomide—a drug used to treat multiple myeloma and
leprosy—requires certification to prescribe because it can cause fatal birth defects
James H. Kim & Anthony R. Scialli, Thalidomide: The Tragedy of Birth Defects and
the Effective Treatment of Disease, 122 TOXICOLOGICAL SCIS. 1, 1–2 (2011). But
because it treats multiple myeloma and leprosy, stigma is not an additional barrier. Thalomid REMS, FDA, https://www.accessdata.fda.gov/drugsatfda_docs/
rems/Thalomid_2017-06-27_REMS_Document.pdf [https://perma.cc/G9HLYYCV].
120
Note: the cost of mifepristone has recently decreased after the introduction
of a generic. See Anna North, America’s First Generic Abortion Pill, Explained, VOX
(Aug. 20, 2019), https://www.vox.com/identities/2019/8/20/20750226/abortion-pill-mifepristone-pregnancy-genbiopro-mifeprex-generic [https://perma.cc/
P2Q2-UQLQ] (noting that the producer of the generic version of Mifeprex expected
that the introduction of the generic to the market would lead prices to decrease).
121
Wendy V. Norman & Judith A. Soon, Requiring Physicians to Dispense
Mifepristone: An Unnecessary Limit on Safety and Access to Medical Abortion, 188
CANADIAN MED. ASS’N J. E429, E429 (2016).
122
Id.
123
DAVID S. COHEN & CAROLE JOFFE, OBSTACLE COURSE: THE EVERYDAY STRUGGLE
TO GET AN ABORTION IN AMERICA 223 (2020).
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124
By simply allowing mifepristone to be distributed by a pharmacy, it is
estimated that “the number of medication abortion providers among ob-gyns in
the United States would likely increase from less than one-quarter of these physicians to 31 percent.” Id.
125
Id. In a recent study, forty-three percent of internal medicine primary care
providers believed medication abortion was within their scope of practice and
were interested in offering it. Tierney Wolgemuth et al., Perspectives of Internal
Medicine Physicians Regarding Medication Abortion Provision in the Primary Care
Setting, 104 CONTRACEPTION 420, 421 (2021).
126
NAF Releases 2019 Violence & Disruption Statistics, supra note 116.
127
See Cynthia Greenlee, A Short History of Abortion-Related Boycotts, Rewire News Group (May 23, 2019), https://rewirenewsgroup.com/article/2019/
05/23/a-short-history-of-abortion-related-boycotts/ [https://perma.cc/L6EYHYW2].
128
Cory Stern, CVS and Walgreens are completely dominating the US drugstore industry, Yahoo (July 29, 2015), https://www.yahoo.com/entertainment/
s/cvs-walgreens-completely-dominating-us-211840229.html [https://perma.cc/
A5CS-ZRUS].
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the capacity to dispense it, their patients may not request it
frequently enough to justify having it in stock. It would have
been entirely reasonable for doctors to decide they either did
not want, or could not handle, these extra administrative burdens.124 Studies show that more physicians would be willing
to become certified to prescribe mifepristone if the drug could
be distributed as almost all other drugs—through a
pharmacy.125
The fact that the FDA recently removed the in-person dispensing requirement and allowed pharmacies to dispense
mifepristone is an important step forward. But its decision to
impose a certification requirement on pharmacies will only duplicate the harmful effects associated with the provider certification requirement, making it unlikely that the average
pharmacy will opt into carrying the drug. Similar to the concerns of providers, pharmacies with physical storefronts might
worry about vandalism, arson, or threats to their employees if
their certification status becomes known.126 The fact that
pharmacies are business entities creates additional considerations. The antiabortion movement is known to stage boycotts,
which could harm pharmacies’ business interests.127 And unlike individual providers, who might be willing to face some of
the risks of certification due to a deep moral conviction about
the necessity of abortion, pharmacies will only endure these
risks if they are outweighed by financial benefits. Certainly,
some pharmacies, especially mail-order pharmacies, will be incentivized to participate and take advantage of this new business, but it is less likely that the big corporate chains most
Americans rely on128 will opt in. Indeed, as this Article was
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129
Cynthia Koons, The Abortion Pill Is Safer Than Tylenol and Almost Impossible to Get, BLOOMBERG (Feb. 17, 2022), https://www.bloomberg.com/news/features/2022-02-17/abortion-pill-mifepristone-is-safer-than-tylenol-and-almostimpossible-to-get.
130
See David S. Cohen & Krysten Connon, Living in the Crosshairs: the Untold Stories of Anti-Abortion Terrorism ix–x (2015) (noting that “partly because
abortion providers are not safe, there are very few abortion providers in the United
States”).
131
See Jones & Jerman, supra note 6, at 6.
132
Jones & Jerman, supra note 6, at 16.
133
Id. at 9.
134
Id. at 16.
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coming to press, Walgreens announced that it would not seek
certification.129
Though these rules are technical, they have a big impact
on access to early abortion. First, because the mifepristone
REMS makes it difficult for average healthcare providers to
prescribe medication abortion, there are fewer providers to provide abortion care. Thus, it can be more difficult for people to
find a provider and more difficult for the small number of providers to meet the demand.130 As discussed in more depth in
Section IV, this is an especially important concern as we face
the potential end of Roe v. Wade, where states with abortionfriendly policies may need to dramatically increase their number of abortion providers to meet the increase in demand from
out-of-state patients.
Second, the certification requirements effectively isolate
abortion care into clinics outside of the traditional healthcare
system because the REMS disincentivizes regular providers
from offering this care. And as a result, the vast majority of
certified providers are those that already have an abortion
practice at abortion and family-planning clinics.131 As of 2017,
it was estimated that only 261 physician offices in the United
States offered abortion services (providing only 1% of abortions132), while abortion and family planning clinics provide
95% of abortions.133 The remainder of abortions occur in hospitals.134 The removal of the in-person dispensing requirement
will likely lead to more physician offices providing abortions,
but eliminating the REMS entirely would certainly lead to
more. Though we have yet to see the effects of the pharmacy
certification requirement, we can expect that the certification
process will similarly disincentivize traditional pharmacies
from dispensing abortion medication—again, isolating abortion
care outside of traditional healthcare settings.
This isolation of abortion care was particularly problematic
when patients were required to pick up the medication in per-
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son, meaning they needed to travel to a clinic.135 Some states
have only a handful of clinics left—five states (as of 2017) only
had one136—meaning that women in those states would often
need to travel long distances to get their medication. Long
travel often required women to pay extra travel costs, find
childcare, and miss work, in addition to facing harassment
from protesters.137 Given that three quarters of abortion patients are low income, these costs made abortion much more
difficult to access.138 This physical separation from the rest of
the healthcare system also contributes to abortion stigma.139
The REMS is not the only barrier that might prevent interested providers from prescribing mifepristone. Physicians
would also need to become acquainted with the state laws governing abortion, which apply to medication abortion. For instance, they must abide by state mandated waiting periods and
disclosures.140 These barriers, however, can be fixed with physician outreach and education, while the REMS and similar
state laws impose logistical challenges that are more difficult to
combat. The stigma associated with providing abortion might
be more difficult to overcome, but allowing providers to prescribe mifepristone as any other drug—i.e., without becoming
certified and with dispensing from traditional pharmacies—
would certainly help assuage fears of harassment.
2. Prohibiting Telemedicine for Abortion
Another significant barrier associated with the mifepristone REMS is that until very recently, it prevented a pure model
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135
See Elizabeth Raymond et al., TelAbortion: Evaluation of a Direct to Patient
Telemedicine Abortion Service in the United States, 100 CONTRACEPTION 173, 174
(2019).
136
Jones & Jerman, supra note 6, at 17.
137
Raymond et al., supra note 135, at 174.
138
Abortion Patients Are Disproportionately Poor And Low Income, GUTTMACHER
INST. (May 9, 2016), https://www.guttmacher.org/infographic/2016/abortionpatients-are-disproportionately-poor-and-low-income [https://perma.cc/9KJQMUL3].
139
CAROL SANGER, ABOUT ABORTION: TERMINATING PREGNANCY IN TWENTY-FIRSTCENTURY AMERICA 22–23 (2017) (“A network of rules whose purpose is to persuade
pregnant women that what they are doing is wrong can make securing an abortion feel shady and crime-like. Clinics are isolated from the regular medical
facilities that provide most other forms of health care.”).
140
See generally, An Overview of Abortion Laws, GUTTMACHER INST. (May 1,
2021), https://www.guttmacher.org/state-policy/explore/overview-abortionlaws?gclid=EAIaIQobChMIvY6L66u-6gIVIfC1Ch06UAHoEAAYA
SAAEgJ6UPD_BwE# [https://perma.cc/P2JU-KBEY] (giving an overview of abortion laws in the United States).
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of telemedicine from coming to fruition.141 As discussed in
more depth in Section IV, abortion will become remarkably
more accessible when abortion patients can meet with a provider remotely from home and receive the abortion medication
by mail.142
Over the course of the COVID-19 pandemic, telemedicine
for abortion care quickly changed from a future dream to an
urgent necessity.143 Not only might women delay an abortion
to avoid an infection risk in a clinic, but for a while, some
women were entirely unable to access clinic-based care.144 The
pandemic made travel much more difficult, especially for those
dependent on public transportation.145 And many clinics
closed temporarily, either due to state orders or because providers could not come in; others dramatically reduced capacity
to try to reduce infection risk, leading to long wait times that
caused woman to pass the ten-week mark entirely.146 Despite
these hardships, the REMS demanded in-person pickup.
Women of color, rural women, and low-income women are
always disproportionately harmed by disruptions to abortion
care, but this was especially pronounced in the pandemic.147
Not only were these women less able to afford the expense and
hurdles of long-distance travel to an abortion clinic, but they
were at much greater risk of contracting and dying of COVID19 to do so: “[T]hree-quarters of abortion patients have low
incomes, making them more likely to rely on public transporta-
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Megan K. Donovan, Improving Access to Abortion Via Telehealth, 22
GUTTMACHER POL’Y REV. 23, 26 (2019). The REMS allowed abortion providers to
use a limited telemedicine model, where patients who are physically present at a
clinic can visit with a doctor who is not physically present via videoconference.
Julia E. Kohn et al., Medication Abortion Provided Through Telemedicine in Four
U.S. States, 143 OBSTETRICS & GYNECOLOGY 343, 344 (2019); Donovan, supra note
141, at 24 (noting that this model exists in at least ten states).
142
See COHEN & JOFFE, supra note 123, at 222.
143
See Laurie Sobel, Amrutha Ramaswamy, Brittni Frederiksen & Alina Salganicoff, State Action to Limit Abortion Access During the COVID-19 Pandemic,
KAISER FAM. FOUND. (Aug. 10, 2020), https://www.kff.org/coronavirus-covid-19/
issue-brief/state-action-to-limit-abortion-access-during-the-covid-19-pandemic/
[https://perma.cc/6QWV-JTZ7] (“[A]ccess is further challenged by difficulties
traveling when a stay at home order is in effect, additional costs related to waiting
periods and other delays, the loss of jobs, the risk of exposure to the coronavirus,
and the uncertain future of the COVID-19 outbreak.”).
144
See id.
145
Greer Donley, Beatrice A. Chen & Sonya Borrero, The Legal and Medical
Necessity of Abortion Care Amid the COVID-19 Pandemic, 7 J.L. & BIOSCIENCES 1,
13 (2020).
146
Id. at 2, 11.
147
Id. at 13; Plaintiff’s Memorandum of Law in Support of Motion for Preliminary Injunction at 28, ACOG v. FDA, 472 F. Supp. 3d (D. Md. 2020) (No. 8:20-cv01320-TDC).
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tion to get to a clinic to pick up their medication. Such patients
must bear further risk of exposure while they travel, sometimes
for several hours each way, to clinics often located far from
their homes.”148 Given that “COVID-19’s mortality rate is three
times higher for Black and Hispanic individuals than non-Hispanic White individuals,” this additional and unnecessary exposure had life-threatening consequences.149
Telemedicine created an obvious solution to this problem—
after all, there is no medical justification for making patients
pick up their prescription in person. For these reasons, the
U.K. started allowing the remote administration of abortion
medication during the pandemic,150 as other countries, like
Australia, had implemented even before the pandemic began.151 When the FDA under the Trump administration temporarily suspended the in-person requirements of other
medications’ REMS, including opioids, but refused to do the
same for mifepristone,152 a medical organization sued the FDA
and won a preliminary injunction. That injunction meant that
for the first time, many Americans began to receive fully remote
abortion care.153 Though the Supreme Court eventually reinstated the in-person dispensing requirement,154 in the
meantime, researchers collected data demonstrating that there
was no increased incidence of adverse events when the inperson dispensing requirement was suspended. As a result,
the Biden administration decided to temporarily, and then permanently, remove the in-person dispensing requirement.155
The imposition of a REMS is a dramatic tool to ensure risky
drugs are prescribed and dispensed in the safest manner possible. The next section explores whether mifepristone is risky
enough to warrant a REMS, and if not, whether the harms of
the REMS outweigh any benefits. It concludes that mifepristone fails to meet the statutory criteria for a REMS because the
148
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FDA v. ACOG, 141 S.Ct. 578, 582 (2021) (Sotomayor, J., dissenting).
Id.
150
Elizabeth C. Romanis, Jordan A. Parsons, & Nathan Hodson, COVID-19
and Reproductive Justice in Great Britain and the United States: Ensuring Access
to Abortion Care During a Global Pandemic, 7 J.L. & BIOSCIENCES 1, 8 (2020).
151
Paul Hyland, Elizabeth G. Raymond & Erica Chong, A Direct-to-Patient
Telemedicine Abortion Service in Australia: Retrospective Analysis of the First 18
Months, 58 AUSTL. & N.Z. J. OBSTETRICS & GYNECOLOGY 335, 336 (2018).
152
See POLICY FOR CERTAIN REMS REQUIREMENTS DURING THE COVID-19 PUBLIC
HEALTH EMERGENCY, supra note 110, at 7 n.13; ACOG, 141 S. Ct. at 579
(Sotomayor, J., dissenting) (noting that the FDA subjected mifepristone to disparate treatment).
153
See infra Section IV.
154
ACOG, 141 S. Ct. at 578.
155
See FDA Letter, supra note 14, at 25-38.
149
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benefits of the drug outweigh the risks even without any distribution limitations.
II
THE MIFEPRISTONE REMS IS UNNECESSARY, HARMFUL, AND
IMPROPER UNDER THE STATUTE
The mifepristone REMS has come under increasing attack
in recent years. Many physician organizations, including the
American Medical Association, the American College of Obstetricians and Gynecologists (ACOG), and the American Academy
of Family Physicians, have issued statements concluding that
the REMS serves no medical purpose.156 Below, I argue that
these negligible benefits are outweighed by significant harms.
Not only does the REMS reduce access to abortion throughout
the United States—which can cause physical, mental, and
emotional harms—and increase abortion stigma, it may also
increase a reliance on self-managed abortion, where women
buy the drug online without the assistance of a doctor. The
REMS is also impacting other aspects of reproductive healthcare. Women suffering from a missed or incomplete miscarriage, for instance, have less access to the drug because of the
REMS,157 even though a combination of mifepristone and misoprostol is more effective at managing these miscarriages than
misoprostol alone.158
A. The Benefits of the Mifepristone REMS are Negligible
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156
Improving Access to Mifepristone for Reproductive Health Indications, ACOG
(June 2018), https://www.acog.org/clinical-information/policy-and-positionstatements/position-statements/2018/improving-access-to-mifepristone-for-reproductive-health-indications [https://perma.cc/VJ53-X8YJ]; Letter to the FDA,
AAFP (Mar. 25, 2020), https://www.aafp.org/dam/AAFP/documents/advocacy/
legal/administrative/LT-FDA-REMSFlexibility-032520.pdf [https://perma.cc/
6GCF-GB9J]; Mifepristone, AMA POL’Y (2018), https://policysearch.amaassn.org/policyfinder/detail/mifepristone?uri=%2FAMADoc%2FHOD.xml-H100.948.xml [https://perma.cc/XF9A-JQNN].
157
See Amanda Allen & Cari Sietstra, Miscarriages Are Awful, and Abortion
Politics Make Them Worse, N.Y. TIMES (June 22, 2021), https://
www.nytimes.com/2021/06/22/opinion/miscarriage-abortion.html [https://
perma.cc/N79Y-3L3X].
158
Divyah Nagendra et. al., Cost-effectiveness of Mifepristone Pretreatment for
the Medical Management of Nonviable Early Pregnancy: Secondary Analysis of a
Randomized Trial, JAMA NETWORK OPEN 1, 7 (2020).
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As highlighted above, the safety data on mifepristone is
extensive. The FDA has been tracking adverse events closely
since the drug was approved in 2000. According to the drug’s
label, which was last modified in 2016, 0.03-0.5% of women
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159
Label for Mifeprex (mifepristone) tablets, FDA 8, https://
www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf
[https://perma.cc/Z53F-2SYL].
160
Id.
161
Mifeprex REMS Study Group, supra note 6, at 791.
162
Questions and Answers on Mifeprex, supra note 20.
163
Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/
2018, FDA, https://www.fda.gov/media/112118/download [https://perma.cc/
X5UD-B246].
164
Questions and Answers on Mifeprex, supra note 20.
165
Analysis of Medication Abortion Risk and the FDA report, “Mifepristone U.S.
Post-Marketing Adverse Events Summary through 12/31/2018”, ADVANCING NEW
STANDARDS IN REPROD. HEALTH (April 2019), https://www.ansirh.org/sites/default/files/publications/files/mifepristone_safety_4-23-2019.pdf [https://
perma.cc/65WV-YRM4].
166
Id.
167
Id.
168
Id.
169
Mifeprex REMS Study Group, supra note 6, at 792.
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who took mifepristone needed a blood transfusion, 0.2% of
women experienced sepsis, and 0.04-0.6% of women needed
hospitalization.159 The risk that someone who had taken
mifepristone would make a visit to the ER was slightly higher,
at 2.9-4.6%.160 These adverse events are all treatable without
any permanent issues.161 FDA’s website notes that “[a]s of
December 31, 2018, there were reports of 24 deaths of women
associated with Mifeprex since the product was approved in
September 2000”162 compared to 3.7 million women who had
taken the drug.163 However, these “adverse events cannot with
certainty be causally attributed to mifepristone.”164 There is
some reason, for instance, to believe that at least eleven of the
deaths were unrelated to the drug.165 But even assuming
mifepristone caused all twenty-four deaths, the risk of death
from the drug would be 0.65 deaths per 100,000 (or
0.00065%).166
The adverse events listed above are serious and should not
be minimized, but all drugs have some risk of serious adverse
events, and the vast majority of them are not subject to a
REMS. For instance, phosphodiesterase type-5 inhibitors,
which include Viagra, have a fatality rate of four deaths per
100,000, which is roughly six times higher than mifepristone,
yet it is not subject to a REMS.167 Penicillin’s fatality rate is
two deaths per 100,000, roughly three times higher than
mifepristone, but again, it is not subject to a REMS.168 And
drugs with similar risks, like anti-coagulants, are available at
all pharmacies without a REMS.169 Finally, the background
risk associated with the alternative—carrying the pregnancy to
term—is also much higher: “the pregnancy related mortality
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Analysis of Medication Abortion Risk and the FDA report, supra note 165.
Improving Access to Mifepristone for Reproductive Health Indications, supra
note 156; CTR. FOR DRUG EVALUATION & RSCH., supra note 99, at 10.
172
CTR. FOR DRUG EVALUATION & RES., supra note 99, at 10.
173
Id.
174
See Raymond et al., supra note 135, at 175.
175
Hyland, Raymond, & Chong, supra note 151, at 337–38.
176
Daniel Grossman & Philip Goldstone, Mifepristone by Prescription: A Dream
in the United States but Reality in Australia, 92 CONTRACEPTION 186, 186 (2015);
Sarah Raifman, Megan Orlando, Sally Rafie, & Daniel Grossman, Medication
Abortion: Potential for Improved Patient Access Through Pharmacies, 58 J. AM.
PHARMACIST ASS’N 377, 379–80 (2018).
177
See FDA Letter, supra note 14.
171
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ratio is eighteen deaths per 100,000 live births, and it is even
higher for Black women—forty deaths per 100,000 live
births.”170
Moreover, it is worth noting that the FDA approved
mifepristone without a REMS under the brand name Korlym
when used to treat Cushing’s Syndrome, a condition related to
exposure to excessive amounts of the hormone cortisol.171
Though the agency’s risk-benefit calculus will inevitably differ
when the same drug is used to treat a different condition, the
risks are larger when mifepristone is used for Cushing’s Syndrome. “Korlym is taken in higher doses, in a chronic, daily
fashion unlike the single 200 mg dose of Mifeprex” that is used
for abortion; as a result, “the rate of adverse events with
Mifeprex is much lower.”172 Nevertheless, patients can buy
Korlym through a specialty pharmacy and have it delivered
directly to their home.173
One could always speculate that mifepristone’s safety record is so good because of the REMS, and therefore, the REMS
is necessary. But at least with the in-person dispensing requirement, data has proved the opposite. For instance, in
2019, a team of researchers published a study in American
women showing that medication abortion was safe and effective with telehealth.174 A similar study was conducted on over
1,000 women in Australia with similar results: the medication
was effective at ending the pregnancy in 96% of the patients,
3% needed a procedure to finish the abortion, and 3% were
admitted to a hospital.175 This data supports the experiences
in other countries, like Mexico, Australia, and parts of Canada,
where mifepristone is safely filled by pharmacists without an
in-person appointment.176 And most recently, data collected
when the in-person dispensing requirement was temporarily
suspended demonstrated that there were no increases in adverse events.177
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See Mifeprex REMS Study Group, supra note 35, at 792.
Plaintiffs’ Motion for Summary Judgement at 12–13, 29, Chelius v. Becerra
sub nom. Chelius v. Azar, No. 1:17-cv-00493-JAO-RT 11–12 (Nov. 27, 2019); FDA
v. ACOG, 141 S. Ct. 578, 579 (2021) (Sotomayor, J., dissenting).
180
Plaintiffs’ Motion for Summary Judgement, at 12–13.
181
Plaintiff’s Memorandum of Law in Support of Motion for Preliminary Injunction at 25, ACOG v. FDA, 472 F. Supp. 3d (D. Md. 2020) (No. 8:20-cv-01320TDC). The ACOG continued, “[t]here is no other drug that the FDA treats in this
manner . . . and for evident reason: it plainly serves no medical interest to dictate
where a patient is standing when handed a pill she will put in her pocket to
swallow later.” Id. at 26.
182
Mifeprex REMS Study Group, supra note 35, at 793.
183
June Med. Servs. L.L.C. v. Russo, 140 S. Ct. 2103, 2172 (2020) (Gorsuch,
J., dissenting) (“Clinics have even hired physicians whose specialties were unrelated to abortion—including a radiologist and an ophthalmologist.”).
179
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These results are not surprising given that the REMS is not
actually correlated with any of mifepristone’s safety risks.
First, the requirement (now removed) that a woman obtain the
drug from a medical facility does nothing to reduce her risk of
hemorrhage, infection, or incomplete abortion, all of which
would all take place at home.178 It is worth noting that the FDA
only subjects sixteen other drugs (of roughly 20,000 FDA-regulated drugs) to an ETASU that requires a patient to obtain a
medication in a clinic.179 Of those sixteen drugs, all must be
taken in the presence of a doctor because the drug requires
intravenous administration, could cause an immediate adverse
reaction that a physician must monitor, or is highly addictive.180 None of those three justifications would apply to
mifepristone, which is a single-use drug, administered by the
patient, that does not cause immediate adverse events. It is for
this reason that ACOG concluded that the in-person dispensing requirement is “medically unnecessary and illogical on its
face: it requires patients to obtain a pill only in clinical settings,
even when they are not receiving any clinical services at that
time and will take the medicine at home without clinical
supervision.”181
Second, because almost any provider could become certified to prescribe mifepristone, the certified provider requirement is largely “an empty formality,”182 aimed largely at
discouraging mifepristone’s provision than credentialling providers. Conservative states have often pointed to the fact that
any healthcare provider can become certified to prescribe
mifepristone as evidence that additional credentialing is necessary when passing state abortion laws. For instance, in a recent abortion case before the Supreme Court, June Medical,
Louisiana criticized the abortion clinic for hiring an ophthalmologist and radiologist to provide medication abortion.183
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This is not to suggest these providers cannot adequately provide medication abortion—the opposite—but to note that any
healthcare provider can meet the certified provider requirement
and safely provide these services. The requirement therefore
provides no independent credentialing function outside of a
license to practice and a plan for dealing with emergencies,
accomplishing nothing more than limiting the number of providers offering early abortion care. Though we do not yet know
what the pharmacy certification requirement will contain, one
can suspect that it will be subject to the same criticism.
The final component of the mifepristone REMS—that patients must sign a Patient Agreement Form—is also unnecessary given that medical ethics requires providers to counsel
patients on the risks and benefits of all medications, and tort
law provides recourse when they fail to do so. Even the FDA’s
own scientists recommended removing the Patient Agreement
Form in 2016 because it was duplicative of informed consent.184 Though this requirement has a much less significant
impact on abortion access, it is still exceptional and redundant. Taken together, the mifepristone REMS confers marginal, if any, benefits to patients. If the REMS did not create
significant harms, it may not matter that the REMS is unnecessary, but as discussed below, the harms are substantial.
B. The Harms of the Mifepristone REMS are Large
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184
Joint Stipulation of Facts at 13–14, Chelius v. Azar, No. 1:17-cv-00493JAO-RT (D. Haw. Nov. 27, 2019).
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The most significant harm associated with the mifepristone
REMS is the reduced access to early and safe abortion. Such
reduced access leads to delays in seeking care, which can force
patients to receive a more expensive and risky surgical abortion
procedure, increase their reliance on self-managed abortion,
and even risk the possibility of being timed out of receiving
abortion care altogether by exceeding the gestational age limits
of state abortion bans. Women who are unable to get an abortion must experience the much greater risks of childbirth and
are more likely to have mental and physical health issues over
time. These harms disproportionately fall on poor women, rural women, and women of color.
As noted in Section I.C, the certification and in-person dispensing requirements made it undesirable for physicians who
do not typically provide abortions to prescribe and dispense
mifepristone. The result was that only 261 physician offices
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Id. at 14.
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Id. at 3; Holly Yan, These Six States Have Only One Abortion Clinic Left.
Missouri Could Become the First with Zero, CNN (June 21, 2019), https://
www.cnn.com/2019/05/29/health/six-states-with-1-abortion-clinic-map-trnd/
index.html [https://perma.cc/BXH5-DLZA].
188
Jones, Witwer & Jerman, supra note 6, at 3.
189
Erica Chong et al., Expansion of a Direct-To-Patient Telemedicine Abortion
Service in the United States and Experience During the COVID-19 Pandemic, 104
CONTRACEPTION 43, 44 (2021).
190
Raymond et al., supra note 135, at 174.
191
Id.
192
Jenna Jerman, Lori Frohwirth, Megan L. Kavanaugh & Nakeisha Blades,
Barriers to Abortion Care and Their Consequences for Patients Traveling for Services: Qualitative Findings from Two States, 49 PERSPS. IN SEXUAL AND REPROD.
HEALTH 95, 95 (2017).
193
Raymond et al., supra note 135, at 174.
186
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provided medication abortion in 2017, providing only 1% of
abortions in the United States.185 The only providers with an
incentive to jump through the hoops of the mifepristone REMS
are those at abortion and family planning clinics, which provide 95% of abortions in this country.186 Thus, the REMS has
contributed to the segregation of abortion care outside of traditional healthcare settings.
This reality meant that the overwhelming majority of women obtained an abortion at a clinic. But the number of clinics
is steadily dropping, and six states only have one abortion provider left.187 From 2011 to 2014, there were six percent fewer
clinics in the United States; the numbers are starker in the
South and Midwest, where the number of clinics had decreased
thirteen and twenty-three percent respectively.188 “In 2017,
95% and 94% of counties in the Midwest and the South, respectively, did not have a facility that provided abortion
care.”189 As a result, many people do not live within 100 miles
of a clinic.190 When the in-person dispensing requirement was
in effect, these long distances made abortion care even more
expensive as patients needed to take time off work, procure
childcare, and pay for travel costs.191 “Given that 75% of abortion patients were poor or low-income in 2014, any additional
barriers to abortion care—including travel and its associated
costs, such as lost wages and expenses for child care, transportation and accommodations—may be significant for many women.”192 And “[e]ven people who live near a clinic may have
difficulty attending in person due to scheduling conflicts, long
wait times for appointments, the high cost of travel, child care,
and lost wages, concerns about confidentiality, and anticipated
harassment at clinics.”193
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For these reasons, the REMS’s effect of funneling abortion
care into clinics—and until very recently, requiring patients to
show up in person—caused some patients to delay abortion
care, leading to a more complicated, risky procedure.194 Each
week an abortion is delayed increases the risk of death from the
procedure by 38%.195 Patients who must travel more than fifty
miles to a clinic are more likely to seek an abortion in the
second trimester, and those who must travel more than three
hours to a clinic are more likely to need an abortion at or after
twenty weeks.196 Delayed abortions can also be more expensive and difficult to find: “If a first-trimester abortion is delayed
until the second trimester, this would result in increased and
perhaps prohibitive cost and access barriers, as second trimester abortions are more expensive, require more time (2-3 days),
and have fewer providers able to perform them.”197 Consequently, “delays may ultimately impede women from having an
abortion procedure entirely.”198 “For example, among a group
of women denied an abortion because of gestational age limits,
85% reported procedure and travel costs as the primary reason
for not obtaining an abortion elsewhere.”199
When women are denied access to an abortion, it comes at
a cost to their health. In the landmark Turnaway Study, researchers compared women who had been denied abortions
from those able to obtain them. They found:

43781-crn_107-3 Sheet No. 17 Side A

Compared to women who received abortions, those who were
denied abortion were more likely to experience financial distress that was sustained for years following the intended
abortion. Women denied abortion also had higher rates of
anxiety and stress, and lower self-esteem and life satisfaction
in the short term, and were more likely to experience potentially life-threatening conditions associated with pregnancy
such as preeclampsia and postpartum hemorrhage. These
women were also more likely to report worse long-term physical health.200
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THE NAT’L ACADS. SCIS., ENG’G, AND MED., THE SAFETY AND QUALITY OF ABORCARE IN THE UNITED STATES 10 (2018).
195
Linda A. Bartlett et al., Risk Factors for Legal Induced Abortion–Related
Mortality in the United States, 103 OBSTETRICS & GYNECOLOGY 729, 731 (2004).
196
Rachel K. Jones & Jenna Jerman, Characteristics and Circumstances of
U.S. Women Who Obtain Very Early and Second-Trimester Abortions, 12 PLOS
ONE 1, 12 (2017); Diana Greene Foster & Katrina Kimport, Who Seeks Abortions
at or after 20 Weeks?, 45 PERSPS. SEXUAL & REPROD. HEALTH 210, 212 (2013).
197
Donley, Chen & Borerro, supra note 145, at 11.
198
Id.
199
Jerman, Frohwirth, Kavanaugh & Blades, supra note 192, at 95.
200
Donley, Chen & Borerro, supra note 145, at 11 (describing results from the
Turnaway study).
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For instance, the risk of death is approximately fourteen times higher for
birth than abortion. Elizabeth G. Raymond & David A. Grimes, The Comparative
Safety of Legal Induced Abortion and Childbirth in the United States, 119 OBSTETRICS & GYNECOLOGY 215, 215 (2012).
202
Black Women’s Maternal Health: A Multifaceted Approach to Addressing
Persistent and Dire Health Disparities, NAT’L P’SHIP FOR WOMEN & FAMS. (2018),
https://www.nationalpartnership.org/our-work/health/reports/black-womensmaternal-health.html [https://perma.cc/7N3Z-FJU3].
203
Grossman & Goldstone, supra note 176, at 187.
204
COHEN & JOFFE, supra note 123, at 222–23.
205
See discussion accompanying notes 130-32.
206
Jones & Jerman, supra note 31, at 2.
207
Jerman, Frohwirth, Kavanaugh & Blades, supra note 192, at 98.
208
The Availability and Use of Medication Abortion, supra note 26.
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And of course, the risks associated with pregnancy and birth
are higher than abortion, so any woman denied an abortion
increases her health risks, even if she doesn’t suffer acute pregnancy-related conditions like pre-eclampsia.201 This is especially true for Black women who experience maternal mortality
rates three to four times higher than those of white women.202
By contrast, if mifepristone could be dispensed by average
pharmacies, which are much more prevalent throughout the
United States than clinics, patients could more easily access
early abortion without delays. For instance, when the government in Australia started allowing pharmacies to dispense
mifepristone, early abortion access increased, especially in rural areas.203 Early research in the United States has shown
that more OBGYNs would prescribe mifepristone if it could be
filled at a pharmacy.204 Though the FDA has decided to allow
certified pharmacies to prescribe it, its addition of a pharmacy
certification requirement makes it unlikely that the pharmacies
most Americans rely on (Walgreens and CVS) will choose to
participate, reducing its positive impact.205 Nevertheless,
telemedicine and medication-by-mail, which were also recently
allowed, dramatically improve access to medication abortion,
reducing delays in care.
Another underreported consequence associated with difficulties accessing abortion is that women will turn to self-managed abortion.206 “[C]onsequences of encountering barriers to
abortion care” include women “consider[ing] ending the pregnancy on their own, either with medications (misoprostol,
herbs or home remedies) or by blunt-force physical trauma.”207
Self-managed abortion occurs when “when a person ends a
pregnancy outside the medical care setting, typically by ordering abortion pills online.”208 Though recent data, discussed in
greater detail in Section IV, suggests that self-managed medi-
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See infra subpart IV.B.
Jones, Witwer & Jerman, supra note 6, at 8.
211
Id.
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Id.
213
Jones & Jerman, supra note 31, at 2.
214
Tanya Basu, Activists are helping Texans get access to abortion pills online,
MIT TECH. R. (Sept. 15, 2021), https://www.technologyreview.com/2021/09/15/
1035790/abortion-pills-online-texas-sb8/ [https://perma.cc/4VV9-C785].
215
Catherine Shaffer, REMS Violations Fines, 27 NATURE BIOTECH. 1068, 1068
(2009). Abortions can be completed without mifepristone by simply using misoprostol, which is not subject to a REMS on its own. This is generally considered
less effective and its legal use still requires a physician prescription. Nguyen Thi
Nhu Ngoc et al., Comparing Two Early Medical Abortion Regimens: Mifepristone+Misoprostol vs. Misoprostol Alone, 83 CONTRACEPTION 410, 410 (2011).
216
Megan K. Donovan, Self-Managed Medication Abortion: Expanding the
Available Options for U.S. Abortion Care, 21 GUTTMACHER POL’Y REV. 41, 44 (2018)
[hereinafter Self-Managed Medication Abortion].
210
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cation abortion is safe in most contexts,209 abortion care
through a healthcare provider is still the gold standard and
self-management can come with legal risks.
The rate of self-managed abortion has been increasing in
recent years; though it is difficult to estimate the true number
of these abortions, in 2017, eighteen percent of clinics “reported that they had seen one or more patients for a missed or
failed abortion due to self-induction . . . , up from 12% in
2014.”210 “The majority of these facilities (54%) had seen only
one or two such patients, but four facilities (all high-volume)
reported 50 or more.”211 Unsurprisingly, self-managed abortion is more common in areas with fewer clinics and greater
abortion restrictions: “Reports of self-managed abortion were
highest in the South (25%) and the West (21%), compared with
10% in the Midwest and 14% in the Northeast.”212 The relationship between strict abortion laws and self-managed care is
also supported by “a media analysis,” which “found that interest in self-induced abortion—as measured via Google
searches—was higher in states with restrictive abortion laws
than in states without them.”213 Indeed, organizations that
help women self-manage their abortions have reported a significant increase in requests from Texans since SB8 went into
effect.214213
Self-managed abortion is not legal in the United States.
The only legal way to obtain the FDA-approved medication
abortion regimen is through the REMS protocol.215 Even if the
REMS were removed, legal use of mifepristone and misoprostol
would still require the prescription of a provider unless the FDA
approved them for over-the-counter use, which is not currently
being considered and is a distant goal.216
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Jones, Witwer & Jerman, supra note 6, at 10.
Letter from Aid Access, to Thomas Christl, Director, Food & Drug Admin., 2
(May 16, 2019), https://aidaccess.org/en/media/inline/2019/5/16/
19_05_16_gomperts_letter_and_exhibit_a.pdf [https://perma.cc/H536-Y9YD].
219
Jones, Witwer & Jerman, supra note 6, at 10; Who Are We, AID ACCESS,
https://aidaccess.org/en/page/561 [https://perma.cc/QR3E-ELGT].
220
COHEN & JOFFE, supra note 123, at 226.
221
Warning Letter from Food & Drug Admin., to Aid Access (March 8, 2019),
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aidaccessorg-575658-03082019 [https://perma.cc/
5L4N-AUZG].
222
Letter from Aid Access, supra note 218; Who Are We, supra note 219.
223
See infra subpart IV.B; Letter from Aid Access, supra note 218 (noting that
Aid Access is not aware of any serious adverse event); Donovan, Self-Managed
Medication Abortion, supra note 216.
224
Id.
225
Patel v. State, 60 N.E.3d 1041, 1043 (Ind. Ct. App. 2016).
218
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Nevertheless, pregnant people have found ways to order
these drugs online from international sources. In 2018, an
international organization, Aid Access, began helping Americans access medication abortion through international pharmacies by mail with the assistance of a doctor.217 A person
who contacts Aid Access has an online consultation with a
doctor abroad; if the physician decides the patient meets the
criteria for medication abortion, the drugs will be prescribed,
filled by a pharmacy in India, and mailed to the patient.218 In
2018, over 11,000 U.S. women requested Aid Access’s help,
and the organization filled 2,500 of those requests.219 The following year, 21,000 U.S. women requested care from Aid Access, and more than a third were provided medication.220 On
March 8, 2019, the FDA issued a warning letter to Aid Access
that its actions violated the Food, Drug & Cosmetic Act.221
Nevertheless, the organization has refused to stop offering its
services to American women.222
Though self-managed medication abortion appears to be
safe in most circumstances,223 the FDA has in other contexts
loosened regulations when those regulations caused consumers to seek care outside of the traditional healthcare system,
presumably with greater health risks. For instance, when onerous FDA regulations created a risk that patients might attempt fecal transplants on their own outside of the medical
setting, the FDA relaxed its regulations.224
There are some notable cases that highlight possible legal
and medical risks when the medication is obtained without any
physician involvement. For instance, in 2013, Purvi Patel purchased medication abortion online through a pharmacy in
Hong Kong without any medical consultation.225 Because
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Id. at 1046–47.
See Woman Who Took Abortion Pill Charged in Death of Fetus, CBS NEWS
(June 9, 2015), http://www.cbsnews.com/news/woman-who-took-abortion-pillcharged-in-death-of-fetus/ [https://perma.cc/28TE-ULB3].
228
Raymond, et al., supra note 135, at 363.
229
COHEN & JOFFE, supra note 123, at 228.
230
See Warning, fake abortion pills for sale online!!, WOMEN ON WAVES (last
visited Nov. 7, 2021), https://www.womenonwaves.org/en/page/974/warningfake-abortion-pills-for-sale-online [https://perma.cc/UR9K-Y4VM].
231
See Chloe Murtagh, Elisa Wells, Elizabeth G. Raymond, Francine Coeytaus
& Beverly Winikoff, Exploring the feasibility of obtaining mifepristone and misoprostol from the internet, 97 CONTRACEPTION 287, 291 (2018) (finding no evidence
that mifepristone and misoprostol products sold online were dangerous or
ineffective).
232
Patel, 60 N.E.3d at 1044.
233
Id. at 1062.
234
Woman Who Took Abortion Pill Charged in Death of Fetus, supra note 227.
227
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Patel had underestimated the length of her pregnancy, the
medication caused her to deliver a live baby at home, who died
shortly after birth, and Patel needed urgent medical attention
at the hospital.226 Rare reports of similar cases have also
emerged in recent years.227 Some studies have suggested that
patients’ underestimation of a pregnancy’s length is uncommon; for instance, only 1% of medication abortion patients who
were certain that their last missed period had started less than
seventy-eight days ago were proven wrong on ultrasound.228
But still, the FDA would nonetheless prefer abortion to occur
under the guidance of a U.S. doctor, and “there is widespread
agreement that those attempting an abortion on their own
should have access to a trusted provider if questions arise.”229
There is also the risk that the medication women are buying
online could be fake or impure,230 although this risk seems
low.231 Self-management as an option for abortion, therefore,
should encourage the FDA to remove the REMS and make it
easier for patients to access abortion from their regular
providers.
Moreover, even if the health risks of self-managed abortion
are small, there are serious legal risks. Purvi Patel was prosecuted in Indiana and sentenced to thirty years in prison for
feticide and felony neglect of a minor.232 She served two of
those years before an appellate court invalidated part of her
conviction and sentenced her to time served.233 Jennie McCormack and Kenlissia Jones similarly used medication abortion
to terminate pregnancies outside the ten-week window and
were also prosecuted when they delivered a much older fetus.234 And Jennifer Whalen was sentenced to eighteen
months in jail after purchasing abortion medication for her
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sixteen-year-old daughter online.235 Of course, the legal risks
associated with illegal use of medication abortion almost always impact poor women and women of color
disproportionately.236
Finally, the REMS burdens not only abortion access, but
also access to the best protocol for miscarriage management. A
miscarriage occurs when a fetus or embryo dies independently
in the womb.237 Though the pregnant person’s body typically
expels the dead fetus or embryo, it can take time for the body to
register the death, and thousands of women every year learn on
ultrasound that their pregnancy has ended before having any
symptoms of miscarriage.238 In those cases, patients can
choose whether they want to expedite the miscarriage with
medical intervention or to wait for the miscarriage to end naturally, which can take weeks or longer.239 Many patients understandably do not want to prolong their suffering or grief and opt
for medical intervention.240 Miscarriage management can occur surgically or with medication.241 When patients choose
medication, they are typically only given misoprostol, even
though recent research suggests that the combination of
mifepristone and misoprostol is more effective.242 But because
the REMS requires certification to prescribe mifepristone—and
most OBGYNs are not certified—it is impossible for this regimen to be adopted into regular clinical care, harming people
experiencing miscarriage as well as those who need abortion.243 Part IV further explores the impact that using
mifepristone for miscarriage could have on destigmatizing
abortion care.
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Emily Bazelon, A Mother in Jail for Helping Her Daughter Have an Abortion,
N.Y. TIMES (Sept. 22, 2014), https://www.nytimes.com/2014/09/22/magazine/
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Ushma D. Upadhyay, Nicole E. Johns, Alice F. Cartwright, & Tanya E.
Franklin, Sociodemographic Characteristics of Women Able to Obtain Medication
Abortion Before and After Ohio’s Law Requiring Use of the Food and Drug Administration Protocol, 2.1 HEALTH EQUITY 122, 124 (2018).
237
Missed or Incomplete Miscarriage, MISCARRIAGE ASSN., https://
www.miscarriageassociation.org.uk/information/information-on-coronaviruscovid-19/missed-or-incomplete-miscarriage-information-for-you/ [https://
perma.cc/DG42-VBR3].
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Though the benefits of the mifepristone REMS are marginal
at best, the risks are significant. As explored below, this suggests that mifepristone does not meet the statutory standard
for imposing a REMS because the benefits of mifepristone outweigh the risks without one. And because the REMS is particularly burdensome on patients in rural or underserved areas
and is not commensurate with how the agency treats similar
drugs, it is especially unwarranted.
C. Mifepristone Fails to Meet the Statutory Standard for a
REMS

245
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247
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See Section II.A.

R

06/09/2022 09:20:03

244

43781-crn_107-3 Sheet No. 20 Side A

The FDA may demand a REMS only if it “determine[s]
that . . . a [REMS] is necessary to ensure that the benefits of the
drug outweigh the risks of the drug.”244 When the FDA issues
a REMS with an ETASU as it has done with mifepristone, the
standard is higher and requires the agency to determine that
the drug “is associated with a serious adverse drug experience”
and that the ETASU is necessary “to mitigate a specific serious
risk listed in the labeling of the drug.”245 Furthermore, the
statute requires that the ETASU be “commensurate with the
specific serious risk listed in the labeling of the drug,” “not be
unduly burdensome on patient access to the drug, considering
in particular . . . patients who have difficulty accessing health
care (such as patients in rural or medically underserved areas),” and “conform with elements to assure safe use for other
drugs with similar, serious risks.”246
Given the safety and efficacy of mifepristone, it would be
difficult for the FDA to conclude that mifepristone should be
subject to any REMS—as demonstrated above, the REMS does
not reduce the risks of the drug, so by definition, it cannot be
necessary to “ensure that the benefits of the drug outweigh the
risks.”247 The certification requirement serves no credentialing
function, the patient agreement form is duplicative of informed
consent, and the (recently removed) in-person dispensing requirement does nothing to prevent the risks of the drug that
would occur at home.248 Moreover, the benefits of mifepristone
are larger than the risks even without a REMS. Mifepristone
benefits women by helping them avoid the greater medical
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risks associated with pregnancy and childbirth.249 This alone
would ensure that the benefits of the drug outweigh the drug’s
much smaller risks and was the basis for the FDA’s original
approval. But even beyond those therapeutic benefits,
mifepristone also helps women exercise their constitutional
and human right to control the number and spacing of their
children250—the deprivation of which leads to physical,
mental, and financial challenges.251 It therefore serves important secondary benefits, which the FDA may also be able to
consider in its risk-benefit calculus.252
But even assuming a REMS could be appropriate, the FDA
would surely fail to meet the statutory requirements of an
ETASU. First, the restrictions are not “commensurate with the
specific serious risks listed in the labeling of the drug.”253 As
just described, the REMS requirements are divorced from the
drug’s risks.254 Second, the ETASU for mifepristone does not
“conform with [ETASU] for other drugs with similar, serious
risks.”255 Other drugs with similar, serious risks, like misoprostol, are not subject to any REMS. Drugs that are riskier,
like Viagra and penicillin, also do not have a REMS.256 And
much riskier drugs, like opioids, are subject to more lenient
REMS.257 Even though opioids are highly addictive and have
caused tens of thousands of fatalities per year from overdoses,
the opioid REMS only requires that opioid manufacturers offer
249

Mifeprex REMS Study Group, supra note 6, at 791.
Roe v. Wade, 410 U.S. 113 (1973); see Reproductive Rights, UNITED NATIONS,
https://www.un.org/en/development/desa/population/theme/rights/index.asp [https://perma.cc/G9PD-US7R].
251
See The Harms of Denying a Woman a Wanted Abortion Findings from the
Turnaway Study, ANSRH, https://www.ansirh.org/sites/default/files/publications/files/the_harms_of_denying_a_woman_a_wanted_abortion_4-16-2020.pdf
[https://perma.cc/JDN4-4AUP] (describing the findings from the Turnaway
Study).
252
Though the FDA typically focuses on therapeutic benefits, Patricia Zettler
has documented the FDA’s recent trend of considering non-therapeutic benefits
as well, including public health and cosmetic benefits. See Patricia J. Zettler,
Margaret Foster Riley & Aaron S. Kesselheim, Implementing a Public Health Perspective in FDA Drug Regulation, 73 FOOD & DRUG L.J. 221 (2018); Patricia J.
Zettler, The FDA’s Power Over Non-Therapeutic Uses of Drugs and Devices, 78
WASH. & LEE L. REV. 379 (2021).
253
21 U.S.C. § 355–1(f)(2).
254
See supra Part II.
255
21 U.S.C. § 355–1(f)(2).
256
See supra Part II.
257
Risk Evaluation and Mitigation Strategy (REMS) Document, Opioid Analgesic
REMS Program, U.S. FOOD & DRUG ADMIN. (Sept. 2018), https://
www.accessdata.fda.gov/drugsatfda_docs/rems/
Opioid_Analgesic_2019_11_14_REMS_Document.pdf [https://perma.cc/8NY9PMAC].

R

250

43781-crn_107-3 Sheet No. 20 Side B
06/09/2022 09:20:03

C M
Y K

43781-crn_107-3 Sheet No. 21 Side A

06/09/2022 09:20:03

\\jciprod01\productn\C\CRN\107-3\CRN302.txt

2022]

unknown

Seq: 39

MEDICATION ABORTION

4-JUN-22

13:48

665

258

C M
Y K

06/09/2022 09:20:03

Id.
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), U.S. FOOD
& DRUG ADMIN. (Sept. 2018), https://www.fda.gov/drugs/information-drugclass/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems [https://
perma.cc/B6ZU-CSBY].
260
21 U.S.C. § 355–1(f)(2).
261
Although Many U.S. Women of Reproductive Age Live Close to an Abortion
Clinic, A Substantial Minority Would Need to Travel Far to Access Services,
GUTTMACHER INST. (Oct. 3, 2017), https://www.guttmacher.org/news-release/
2017/although-many-us-women-reproductive-age-live-close-abortion-clinicsubstantial [https://perma.cc/MB8U-99CC].
262
Id.
263
See supra subpart I.C.
264
See Joint Stipulation of Facts at 13–14, Chelius v. Azar, No. 1:17-cv00493-JAO-RT (D. Haw. Nov. 27, 2019).
265
See infra Section I.
259
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training to healthcare providers that prescribe opioids.258 The
FDA acknowledges that “[t]here is no mandatory federal requirement that prescribers or other HCPs take the training and
no precondition to prescribing or dispensing opioid analgesics
to patients.”259
But most importantly, the mifepristone REMS is “unduly
burdensome on patient access to the drug,” especially for “patients in rural or medically underserved areas.”260 “Poor and
low-income women and those who live in rural areas are often
hit hardest by state restrictions that exacerbate long-standing
inequalities in abortion access . . . .”261 Because clinics exist in
urban areas, funneling abortion care through clinics creates
extra burdens for rural women. These burdens were especially
pronounced with the in-person dispensing requirement, which
forced rural women to travel long distances to pick up mifepristone; it also disproportionately harmed poor women, who
struggled the most to afford the additional costs associated
with travel and in-person care.262 It is well documented that
travel time to an abortion or family planning clinic delays care
and reduces access to abortion.263
Furthermore, the FDA’s record for explaining the need for
the REMS is thin. The agency at has never provided a detailed
explanation for how mifepristone meets the statutory definition
for a REMS—i.e., how a REMS is necessary to ensure the benefits of the drug outweigh the harms.264 This might be an accident of history: the restrictions were first approved under a
different statute before the REMS program existed, and then
converted to a REMS in 2011.265 But ever since the REMS has
been in place, the agency has required others to prove the
requirements are unnecessary before removing them. Though
the burden is originally on the FDA to justify the imposition of a
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REMS, once issued, the drug’s sponsor and others bear the
burden of proving there is an “adequate rationale” to modify the
REMS.266 In 2021, when the agency concluded its reconsideration of the mifepristone REMS, it explained that it was retaining the certification and patient agreement form requirements
because no new research has demonstrated that they could be
removed safely.267 Similarly, the agency imposed a new pharmacy certification requirement because there was not sufficient evidence that retail pharmacies could safely dispense
it.268 This burden shifting is problematic in the absence of an
original justification that mifepristone’s benefits can only outweigh its risks with a REMS.
This Section argued that the mifepristone REMS is improper, has few benefits, and contains significant harms. It
also demonstrated that the statutory basis for issuing a REMS,
much less an ETASU, is not met. So why would the FDA have
required it? Abortion exceptionalism. Abortion exceptionalism
is a term that first appeared in legal scholarship around 2012
and describes the phenomenon “in which abortion is singled
out for more restrictive government regulation as compared to
other, similar procedures.”269 Linda Greenhouse and Reva
Siegel have noted that abortion exceptionalism also involves
“the notion that there is a special moral valence to abortion
that, because it concerns the unborn, warrants special forms of
health regulation not imposed on procedures of comparable
risk.”270 Abortion exceptionalism is not new, but it is underexplored in the context of the FDA. I argue below that the FDA’s
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266
RISK EVALUATION AND MITIGATION STRATEGIES: MODIFICATIONS AND REVISIONS,
GUIDANCE FOR INDUSTRY, FOOD & DRUG ADMIN. 12 (June 2020), https://www.fda.gov
/media/128651/download [https://perma.cc/3NP7-D8XL]. The rationale may
include, but is not limited to, the reason(s) why the proposed modification is
necessary; the potential effect of the proposed modification on how the REMS
addresses the serious risk(s) for which the REMS was required, on patient access
to the drug, and/or on the burden on the health care delivery system; and other
appropriate evidence or data to support the proposed change. Id. The sponsor
could also submit a modification request based on a new use of the drug—for
instance, mifepristone’s use in miscarriage management in addition to abortion.
Id. at 12–13.
267
FDA Letter, supra note 14, at 22-24.
268
Id. at 34-35.
269
Ian Vandewalker, Abortion and Informed Consent: How Biased Counseling
Laws Mandate Violations of Medical Ethics, 19 MICH. J. GENDER & L. 1, 3 (2012);
see also Caitlin E. Borgmann, Abortion Exceptionalism and Undue Burden Preemption, 71 WASH. & LEE L. REV. 1047, 1048 (2014) (“‘Abortion exceptionalism’ is a
term that has been used to describe the tendency of legislatures and courts to
subject abortion to unique, and uniquely burdensome, rules.”).
270
Linda Greenhouse & Reva B. Siegel, Casey and the Clinic Closings: When
“Protecting Health” Obstructs Choice, 125 YALE L.J. 1428, 1448 (2016).
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decision to institute the mifepristone REMS is a part of a larger
pattern of bias from the agency that has harmed women’s
health. Though abortion is political, the FDA should not be.
Rather, the agency should act according to its scientific mission and neutrally administer the statute to which it is bound.
III
THE FDA’S TROUBLING PATTERN OF DEVALUING WOMEN’S
HEALTH
Though the mifepristone REMS may seem like an outlier,
the FDA has a troubling history of implicit bias that harms
women’s sexual and reproductive health.
[T]he FDA has shown particular vulnerability to sociopolitical
influences on matters of women’s health. The agency displays a number of biases that distort scientific analysis, from
normative judgments about women’s sexuality to a patronizing sense that women require heightened protection against
the risks posed by otherwise effective drugs.271

Below, I highlight many instances in which the FDA has acted
unusually with regard to women’s sexual and reproductive
health. Some of these instances were overturned by court order or statute; others were resolved only after public pressure
mounted. In almost all cases, advocates attacked the FDA’s
decisions by showing the agency’s unusual treatment compared to other products. Such comparisons can help uncover
biases that may be hidden when any one decision is viewed in
isolation.

The most famous instance of reproductive health bias at
the FDA occurred in its regulation of Plan B. The FDA approved Plan B as emergency contraception in 1999.272 Two
years later, a group of sixty-six organizations petitioned the
FDA to approve the drug for over-the-counter use.273 Obtaining over-the-counter approval was vital for a time-sensitive
drug like Plan B—without it, women and girls could only access
Plan B after a doctor’s appointment that resulted in a prescription. This extra step easily caused days of delays, threatening
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271
Mara Sanders, Sex, Drugs, and Advisory Committees: An Analysis of Pharmaceutical Industry Manipulation of FDA Vulnerability to Sociopolitical Influences
on Matters of Women’s Health, 48 COLUM. HUM. RTS. L. REV. 149, 150 (2017).
272
Tummino v. Torti, 603 F. Supp. 2d 519, 522 (E.D.N.Y. 2009).
273
The Plan B sponsor also submitted a formal SNDA seeking the same overthe-counter approval. Id. at 526–27.
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Id. at 522.
U.S. GOV’T ACCOUNTABILITY OFF., GAO-06-109, FOOD AND DRUG ADMINISTRATION: DECISION PROCESS TO DENY INITIAL APPLICATION FOR OVER-THE-COUNTER MARKETING OF THE EMERGENCY CONTRACEPTIVE DRUG PLAN B WAS UNUSUAL 5–6 (2005).
276
Tummino, 603 F. Supp. 2d at 523.
277
Id.
278
Id.
279
Id. at 545–46.
280
Id. at 545.
281
Id. at 549.
275
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the efficacy of the medication. Plan B is most effective when
people take the drug within twenty-four hours (or, at most,
three days) of unprotected sex.274
The FDA rejected the switch to over-the-counter, even
though its experts recommended approval; this led to a Government Accountability Office (GAO) investigation, which
found that the FDA’s decision was atypical.275 In 2006, the
FDA agreed to allow over-the-counter sale of Plan B but limited
its approval to adult women “despite nearly uniform agreement
among FDA scientific review staff that women of all ages could
use Plan B without a prescription safely and effectively.”276
The manufacturer objected to the restriction that prevented
women under eighteen from purchasing Plan B over-thecounter and sued the agency under the Administrative Procedures Act.
The first time this case made it to court, the Eastern District of New York found that the agency’s decision with regard
to Plan B was contaminated with “political considerations, delays, and implausible justifications.”277 The court also determined that “the FDA’s course of conduct regarding Plan B
departed in significant ways from the agency’s normal procedures regarding similar applications to switch a drug product
from prescription to non-prescription use.”278 In particular,
the court was alarmed that the FDA disregarded an expert
panel and its own staff, who had determined Plan B would be
safe for women and girls of all ages over the counter.279 As a
result, the court held that the FDA had acted arbitrarily and
capriciously.280 The court remanded back to the agency to
reconsider its decision regarding access to Plan B, noting that
because the new Obama administration had replaced the FDA
Commissioner, it expected that the new leadership would ensure that fair scientific review would occur.281
Three years later, the FDA agreed to approve Plan B for
over-the-counter use for all ages. The agency concluded that:
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[T]he product was safe and effective in adolescent females,
that adolescent females understood the product was not for
routine use, and that the product would not protect them
against sexually transmitted diseases. Additionally, the data
supported a finding that adolescent females could use Plan B
One–Step properly without the intervention of a healthcare
provider.282
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Tummino v. Hamburg, 936 F. Supp. 2d 162, 166–67 (E.D.N.Y. 2013).
Id. at 167.
284
Id. (quoting Memorandum from Kathleen Sebelius, Sec’y Health & Human
Servs., to Margaret Hamburg, Comm’r Food & Drugs (Dec. 7, 2011), Case No. 05cv-366, Doc. No. 339-1).
285
Id.
286
Id. at 167–68.
287
Id. at 197.
288
Id. at 170.
289
Id.
290
Id. at 171.
291
Id. at 173–74.
283
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Though this would have ordinarily put the matter to rest, the
Secretary of the Department of Health & Human Services
(HHS), which oversees the FDA, overruled the Commissioner’s
decision.283 The Secretary ordered the Commissioner to deny
the manufacturer’s request on the grounds that “the data submitted for this product do not establish that prescription dispensing requirements should be eliminated for all ages.”284
The Secretary’s main objection was that the data did not adequately take into account the “significant cognitive and behavioral differences between older adolescent girls and the
youngest girls of reproductive age.”285 President Obama
agreed.286
The petitioners sued again, and the court for a second time
held that an agency—this time, HHS—acted arbitrarily and
capriciously.287 The court again relied on the unusual political
involvement in what should have been a scientific decision.288
The court noted that it was the first time the Secretary had
overruled the Commissioner on a drug approval matter289 and
concluded that the Secretary’s rationale was “so unpersuasive
as to call into question her good faith.”290 The court relied on
the fact that less safe drugs were available over-the-counter
with no age restrictions: “levonorgestrel-based contraceptives
would be probably among the safest drugs approved for overthe-counter sale for the pediatric population.”291 The New England Journal of Medicine published an opinion, cited by the
court, which argued the agency’s denial “cannot be based on
issues of safety, since a 12-year-old can purchase a lethal dose
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of acetaminophen in any pharmacy for about $11, no questions
asked. The only documented adverse effects of a $50 dose of
levonorgestrel are nausea and delay of menses by several
days.”292 The court also described the evidence that the prescription requirement for adolescents would delay and even
prevent young women and girls from “accessing the drug
within the short time frame during which it will be effective,
thereby exposing them to increased risk of unwanted pregnancy and making the product’s limited [over-the-counter] status useless.”293
As a result, the court remanded to the agency, ordering it
to allow the over-the-counter sale of Plan B to women and girls
of all ages.294 Though the court acknowledged the political
reasons why Plan B was controversial, it noted that the
agency’s role was quite simple: “the issue in this case involves
the interpretation of a general statutory and regulatory scheme
relating to the approval of drugs for over-the-counter sale. The
standards are the same for aspirin and for contraceptives.”295
The Obama administration decided not to appeal the decision
and instead complied with the order. But the lengthy Plan B
drama lost the FDA and HHS a great deal of credibility.296
“Plan B is an excellent example of what happens when the
public health standard is replaced by a public morality standard that has not been determined by a democratic process
through the appropriate government institutions.”297
B. Importation of Mifepristone for Personal Use

292
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Id. at 171.
Id. at 168 (quoting Wilkinson Decl. ¶ 7, Case No. 12-cv-763, Doc. No. 6).
294
Id. at 197.
295
Id. at 169.
296
For instance, medical journals declared that the government was prioritizing politics over science. See e.g., Alastair J.J. Wood, M.D., Jeffrey M. Drazen,
M.D., & Michael F. Greene, M.D., The Politics of Emergency Contraception, 366
NEW ENG. J. MED. 101, 102 (2012) (“Thus, we once again have a situation in which
political considerations are forming the basis of public health policy—resulting in
another sad day for women.”).
297
John H. Fielder, Ph.D., Ethics and FDA, 61 FOOD & DRUG L.J. 809, 810
(2006).
293
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Long before mifepristone was approved as an abortifacient
and subject to a REMS, the FDA had treated it unusually. In
the decade or so where the drug was approved in European
countries, but not the United States, some American women
attempted to import mifepristone under the personal use ex-
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See Elizabeth A. Silverberg, Looking Beyond Judicial Deference to Agency
Discretion: A Fundamental Right of Access to RU 486?, 59 BROOK. L. REV. 1551,
1551 (1994).
299
Benten v. Kessler, 799 F. Supp. 281, 285 (E.D.N.Y. 1992) (quoting U.S.
FOOD & DRUG ADMIN. REGUL. PROCS. MANUAL 9-71-30(C)).
300
Id.
301
Id. at 286 (quoting U.S. FOOD & DRUG ADMIN. IMPORT ALERT 66–47).
302
Silverberg, supra note 298, at 1551.
303
Id.
304
Benten, 799 F. Supp. at 283.
305
Id. at 289.
306
Id. at 286.
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emption.298 Though the FDA bans the sale of unapproved
drugs, the personal use exemption allows individuals to import
small quantities of drugs for personal use under the supervision of a physician if the drug was used to treat conditions that
were life-threatening, serious, or less serious conditions where
the product “is not known to represent a significant health
risk.”299 The exemption was created in 1989 in response to the
HIV/AIDS crisis, during which time the FDA was heavily criticized for not acting quickly enough to approve life-saving
drugs; the exception helped patients access treatments not approved in the United States without sacrificing the agency’s
rigorous drug approval process.300 Quickly thereafter, members of Congress complained to the FDA that mifepristone—
then known as RU 486—could be permitted under this exemption. The FDA under the Bush administration then issued Import Alert 66-47, which stated that RU-486 was subject to
automatic detention because it “could pose a risk to the safety
of the user.”301
In 1992, Leona Benten traveled abroad and returned to the
United States with a small amount of mifepristone, which had
been prescribed by her doctor to end an early pregnancy.302
She was detained and the drug was seized.303 She sued under
the Administrative Procedures Act.304 The district court
granted her motion for preliminary injunction on the grounds
that the agency failed to follow the required notice and comment procedures in issuing the import alert.305 Though not
central to the court’s analysis, the court noted that the
agency’s determination was politically motivated and inconsistent with its treatment of other drugs: “it appears much more
likely from the history outlined above that the decision to ban
the drug was based not from any bonafide concern for the
safety of users of the drug, but on political considerations having no place in FDA decisions on health and safety.”306 It or-
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dered the FDA to “immediately release the impounded dosage
of RU486 to [the] plaintiff.”307
On appeal, the Second Circuit stayed the injunction.
Benten filed an application to vacate the stay, which the Supreme Court denied in a per curium opinion with no analysis.308 Scholars have suggested that the FDA’s decision was as
politically motivated as its decision over Plan B: “What RU-486
and Plan B have in common . . . is that both were very controversial FDA decisions because of their connection (or perceived
connection, in the case of Plan B) to abortion. In addition, the
FDA appears to have deviated from its standard procedures in
regard to both.”309 “[T]he FDA appears to have responded to
political pressure rather than a public health mandate when it
issued its import alert on RU-486.”310
On November 19, 1990, the House of Representatives
called a hearing to consider the appropriateness of the FDA’s
decision.311 There, many scientists testified that they believed
the FDA’s decision was politically motivated.312 For instance, a
representative from the American Public Health Association
testified: “The FDA should be making their decisions based on
scientific fact, pure and simple. If you allow the FDA to become
politicized as it seems to be in this case, then their credibility
and the credibility of our Government and country suffers dramatically, and the American people will end up suffering.”313
On President Clinton’s third day in office, he ordered the
FDA to reconsider the policy, noting that “RU-486 has been
held hostage to politics.”314 His order stated that “the FDA
appears to have based its decision on factors other than an
assessment of the possible health and safety risks of the
drug.”315 “[I]f the FDA concludes that RU-486 meets the crite307
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Id. at 291.
Benten v. Kessler, 505 U.S. 1084, 1085 (1992).
309
Gillian E. Metzger, Abortion, Equality, and Administrative Regulation, 56
EMORY L.J. 865, 878 (2007).
310
Peter S. Reichertz & Melinda S. Friend, Hiding Behind Agency Discretion:
The Food and Drug Administration’s Personal Use Drug Importation Policy, 9 CORNELL J. L. & PUB. POL’Y 493, 520 (2000).
311
RU 486: The Import Ban and its Effect on Medical Research: Hearing Before
the Subcomm. on Regul., Bus. Opportunities, and Energy of the H. Comm. on Small
Bus., 101st Cong., 2d Sess. (1990).
312
Id. at 31.
313
Id. at 33.
314
Noah, supra note 59, at 578 (quoting President Clinton).
315
Importation of RU-486, Memorandum for the Secretary of Health and
Human Services, 58 Fed. Reg. 7459 (Jan. 22, 1993).
308
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ria for the personal use importation exemption, I direct that
you immediately take steps to rescind Import Alert 66–47.”316
C. Female Sex Drugs
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Jessica Leber, The “Female Viagra” Is Here: The Story of How It Almost
Never Happened, FASTCOMPANY (Aug. 18, 2015), https://www.fastcompany.com/
3049926/the-female-viagra-is-coming-the-story-of-how-it-almost-never-happened [https://perma.cc/SU6X-UXET].
318
Id.
319
Id.
320
Sanders, supra note 271, at 190.
321
Id.
322
Leber, supra note 317.
323
Id.
324
Id.
325
Id.
326
Id.
327
Sanders, supra note 271, at 190–91.
317
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The FDA was again accused of bias—this time with regard
to women’s sexual health—when it refused to approve the female sex drug, flibanserin, which is used to treat hypoactive
sexual desire disorder in women.317 Flibanserin was touted as
the “pink pill,” which could help women increase their sexual
interest.318 In 2010, the FDA first declined to approve the
drug.319 The agency concluded that the eligibility criteria for
the clinical trials were too restrictive, and therefore, the study
results were not generalizable to the broader female population; it found that more data was needed to demonstrate the
product was effective and safe.320 The agency also required
more data on the drug’s interactions with other substances,
including alcohol.321 After the failed FDA review, the pharmaceutical company sponsoring the NDA decided to abandon the
drug instead of investing in more clinical trials.322
Instead, a small pharmaceutical company, Sprout, bought
the rights to the drug and decided to invest in it.323 The company conducted fourteen new clinical trials, composed of over
3,000 women (in addition to the 8,000 women who had participated in the initial clinical trials).324 The results were modest,
but positive—”[o]n average, women on the drug had 0.5 to 1
additional sexually satisfying events per month (from a 2 to 3
‘event’ baseline) compare[d] to those on a placebo.”325 Sprout
resubmitted its NDA in 2013, but the FDA again found that
more data was needed.326 This time, the FDA expressed concerns about the marginal benefit of the drug and the drug’s
safety, especially if used with alcohol.327
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At that point, Sprout helped launch a public interest campaign, called Even the Score, which was run by members of
Congress and a dozen women’s advocacy groups.328 The goal
was to demonstrate that the FDA’s decision reflected bias—the
group frequently noted that Viagra was associated with much
more serious health risks but was approved much more
quickly.329 “I think there’s been some unconscious bias at the
FDA and an overly protective mentality about the risks women
are allowed to undertake when it comes to sexual health, especially compared to men.”330 The FDA rejected claims that gender bias influenced its decision.331
Sprout eventually applied for approval a third time, and an
advisory committee met in 2015 to review the drug again.332
Sprout relied on the same efficacy data from the previous trials
but submitted additional data related to the drug’s safety with
alcohol. At that meeting, the FDA heard testimony from individuals who supported the approval of the drug, including individuals affected by the disorder and women’s rights advocates
generally.333
These speakers often spoke in the language of the women’s
reproductive rights movement, stressing a woman’s right to
sexual autonomy and implying that a rejection of flibanserin
would be an intolerable imposition of patronizing sexual
norms in a treatment decision that should be made privately
between a patient and her doctor.334
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Leber, supra note 317.
Id.
Id.
Sanders, supra note 271, at 177.
Id. at 173.
Id. at 177–78.
Id. at 184.
Id. at 186.
Id. at 187, 189.
Id. at 189.
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The testimony also “implied both that the FDA had patronizingly over-assessed risks that women were capable of evaluating with their doctors, and also undervalued the problem of
female sexual dysfunction.”335 Two women’s health advocates,
however, also testified against approval of the drug, arguing
that the drug’s risks were not worth its modest benefits.336
These speakers accused Even the Score of “an unprecedented
misinformation campaign that hijacked the feminist movement
to pressure the FDA to approve a risky drug for a diagnosis of
dubious legitimacy.”337
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This time, the advisory committee voted to approve the
drug. Though the advisory committee found the benefits marginal, the benefits were statistically significant and clinically
meaningful.338 However, the FDA remained concerned about
the drug’s interaction with alcohol.339 Though Sprout had conducted a study on the interaction of the drug with alcohol, it
surprisingly included almost all men.340 As a result, the committee recommended a REMS.341 The initial REMS only allowed certified providers to prescribe the drug, but after
negotiations with the agency in the years following approval,
the ETASU was removed; now, the REMS only includes a medication guide that informs women of the drug’s risks, especially
with regard to alcohol.342 More recent data appears to suggest,
however, that the drug is both effective and safe to use with
alcohol.343
D. Medical Research in Women and Female Animals
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In addition to bias in approving products, the FDA has
been heavily criticized for its role in excluding women from
medical research. Historically, medical research was conducted primarily in men, after which the results were considered generalizable to both sexes.344 This approach has been
condemned over the past seventy-five years as research
mounted that “women are not just smaller men: male and female bodies differ down to a cellular level.”345 Women and men
are afflicted by different diseases, respond to different treatments, and experience different side effects in response to
drugs.346 The exclusion of women from medical trials has
therefore led to a dearth of research on how to treat women
most effectively.347
338
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Id. at 193.
Id.
340
Id.
341
Id. at 195.
342
Flibanserin REMS, U.S. FOOD & DRUG ADMIN., https://www.access
data.fda.gov/scripts/cder/rems/index.cfm?event=indvRemsDetails.page&REMS=350 [https://perma.cc/NS66-4LTN] (last updated Oct. 2019).
343
James A. Simon, Anita H. Clayton, Sharon J. Parish, Stuart C. Apfel, &
Leah Millheiser, Effects of Alcohol Administered with Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study, 17
J. SEXUAL MED. 83, 89–90 (2020).
344
CAROLINE CRIADO PEREZ, INVISIBLE WOMEN: DATA BIAS IN A WORLD DESIGNED FOR
MEN 201 (2019).
345
Id. at 199; R. Alta Charo, Protecting Us to Death: Women, Pregnancy, and
Clinical Research Trials, 38 ST. LOUIS U. L.J. 135, 140 (1993).
346
CRIADO PEREZ, supra note 344, at 198–99.
347
Id. at 200–01.
339
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Women were historically excluded from medical research
on the grounds that their menstrual cycles introduced too
much variability into the data.348 Of course, this very difference demonstrates the need to study all sexes; if women’s bodies are that different from men’s bodies, then their drug
response could be too.349 It also led to the unfortunate reality
that diseases affecting women were hardly ever studied.350 In
the wake of Roe v. Wade, the FDA decided to explicitly exclude
all women of childbearing potential from participation in earlyphase medical research.351 “The vocal pro-life community, galvanized in the wake of the U.S. Supreme Court’s 1973 Roe v.
Wade decision, expressed concern for unborn fetuses by pushing for stringent limits on women’s research participation.”352
The FDA’s overinclusive and ultimately harmful decision
bowed to political pressure and codified the presumption of the
male norm in medical research.353
In the late 1980s and early 1990s, “a coalition of women’s
health advocates, biomedical researchers, and lawmakers
came up with a strategy to put this knowledge gap on the
public’s radar.”354 In 1992, the Government Accountability Office (GAO) issued a report, titled “Women’s Health: FDA Needs
to Ensure More Study of Gender Differences in Prescription
Drug Testing,” which found that more than 60% of drugs did
not enroll a representative sample of women in their clinical
trials.355 In 1993, President Clinton signed the NIH Revitalization Act, which required all NIH-funded studies to include wo-
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Id. at 202.
MAYA DUSENBERY, DOING HARM: THE TRUTH ABOUT HOW BAD MEDICINE AND LAZY
SCIENCE LEAVE WOMEN DISMISSED, MISDIAGNOSED, AND SICK 32 (2018).
350
CRIADO PEREZ, supra note 344, at 198.
351
FDA was also likely motivated to ban women of childbearing age from
research after the thalidomide scandal, where a drug that was initially thought of
as safe ended up causing over 10,000 birth defects. CRIADO PEREZ, supra note
344, at 201.
352
Christine Grady & Colleen Denny, Research Involving Women, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 407, 409 (Ezekiel J. Emanuel et al.
eds., 2008); see also Charles R. McCarthy, Historical Background of Clinical Trials
Involving Women and Minorities, 69 ACAD. MED. 695, 696 (1994) (“The highly
emotional abortion debate, including its political connotations, had a chilling
effect on research involving women of childbearing potential and human
fetuses.”).
353
Grady & Denny, supra note 352, at 416.
354
DUSENBERY, supra note 349, at 24.
355
U.S. GOV’T ACCOUNTABILITY OFF., GAO-93-17, WOMEN’S HEALTH: FDA NEEDS
TO ENSURE MORE STUDY OF GENDER DIFFERENCES IN PRESCRIPTION DRUG TESTING 2–3
(1992), https://www.gao.gov/assets/220/216966.pdf [https://perma.cc/446XY4EY].
349
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DUSENBERY, supra note 349, at 33.
Id.
358
Id.; Guideline for the Study and Evaluation of Gender Differences in the
Clinical Evaluation of Drugs, 51 Fed. Reg. 39406, 39406 (1993).
359
U.S. GOV’T ACCOUNTABILITY OFF., supra note 355, at 3–4.
360
Id. at 5.
361
DUSENBERY, supra note 349, at 36 (quoting Dr. Jan Werbinski, executive
director of the Sex and Gender Women’s Health Collaborative); Charo, supra note
345, at 151.
362
Id. at 37 (quoting Phyllis Greenberger, the former president of the Society
for Women’s Health Research).
363
Id; FOOD & DRUG ADMIN., FDA ACTION PLAN TO ENHANCE THE COLLECTION AND
AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA (2014), https://www.fda.gov/media/
89307/download [https://perma.cc/WL4X-DJC2].
364
DUSENBERY, supra note 349, at 33.
365
Id. at 34.
357
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men and minorities.356 Thereafter, the FDA abandoned its
policy excluding women of child-bearing age from research and
started to encourage drug companies to include a representative sample of women in all clinical trials.357 In the FDA’s mea
culpa, it admitted that its previous policy had been “rigid and
paternalistic” and may have led to “a paucity of information
about the effects of drugs in women.”358
By 2001, GAO issued another report, which found significant improvement, but also areas of concern.359 For instance,
GAO noted that the FDA lacked any system to track the inclusion of women in research and did not evaluate sex differences
in its review process.360 The lack of analysis into sex differences means that the inclusion of women is not leading to the
information that matters: “it’s been twenty-five years and we
now have a lot of research that includes women but women are
still invisible.”361 “[I]nclusion is one thing, analysis is something else[,] [a]nd that’s not there yet.”362 After a request from
Congress in 2012, the FDA acknowledged this lack of analysis
remained a problem, and in 2014, released a twenty-sevenpoint action plan to “enhance the collection and availability of
demographic subgroup data” for underrepresented populations, including women.363
These policy changes have unfortunately not translated to
serious gains. In 2015, the director of the women’s health research center at Yale Medical School noted that “progress has
been painfully slow—stalling for long periods or sometimes reversing direction—and, consequently, not nearly enough progress has been made.”364 The FDA has been criticized for doing
nothing to improve women’s participation in clinical trials
“apart from dropping the policy that actively excluded
them.”365 Beyond women, the FDA still does not require pre-
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clinical studies to include female animals or cell lines,366 and
many researchers still use exclusively male animals and cell
lines in their research.367 This is despite the fact that sex differences in female animals and cells can also lead to different
outcomes in research.368 As a result, some have questioned:
“how many treatments have women missed out on because
they had no effect on the male cells on which they were exclusively tested?”369 Researchers who focus exclusively on male
cells and male animals are missing possible medical breakthroughs for women’s health.
E. Labeling Regulations in Pregnancy
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366
See Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals,
FOOD & DRUG ADMIN. (Oct. 17, 2019) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conducthuman-clinical-trials-and-marketing-authorization [https://perma.cc/A4WUHKZP].
367
CRIADO PEREZ, supra note 344, at 206.
368
Id.
369
Id. at 207.
370
Greer Donley, Encouraging Maternal Sacrifice: How Regulations Governing
the Consumption of Pharmaceuticals During Pregnancy Prioritize Fetal Safety Over
Maternal Health and Autonomy, 39 N.Y.U. R. L. & SOC. CHANGE 45, 55 (2015).
371
Anne Drapkin Lyerly, Margaret Olivia Little & Ruth Faden, The Second
Wave: Toward Responsible Inclusion of Pregnant Women in Research, 1 INT’L J.
FEMINIST APPROACHES TO BIOETHICS 5, 8 (2008).
372
Frank Hytten, Blood Volume Changes in Normal Pregnancy, 14 CLINICS
HAEMATOLOGY 601, 601 (1985).
373
See Donley, supra note 370.
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Another area where the FDA has shown bias is in its regulations governing the labeling of drugs for use in pregnancy.
Medical research in pregnant women has been almost nonexistent, creating a dearth of information about how pregnant
women metabolize drugs.370 Pregnant women are not just women with bigger bellies: “Pregnancy-related changes in the gastrointestinal tract, the cardiovascular system, the kidneys, and
other organs may profoundly alter the ways that drugs are
processed by the body (pharmacokinetics) or the ways that
drugs act on the body (pharmacodynamics).”371 For instance,
a pregnant woman’s blood volume increases by 50% during
pregnancy, which can have a huge impact on how her body
metabolizes drugs.372
The FDA’s involvement here is related to its labeling regulations, where the agency has historically warned pregnant women about drug risks to their detriment.373 Before 2015, the
FDA required all drugs to be categorized as either A, B, C, D, or
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X, which was supposed to help pregnant women understand a
drug’s safety during pregnancy.374 Category A was the safest; a
drug only received Category A status if there were clinical trials
in pregnant women that failed to show additional risks.375 Because it was so hard to conduct clinical trials in pregnant women, very few drugs were able to meet this standard. But
“[e]ven if a drug [was] able to gain Class A status—a status only
0.7% of drugs hold—the drug label [was required to] contain a
warning against taking the drug unless doing so is clearly
needed.”376 This warning was exclusively required in the pregnancy context; even though the FDA can never rule out drug
risks for any population, it does not recommend any other
population avoid pharmaceuticals that were shown to be safe
in clinical trials.377 Not only was a similar warning never used
for drugs in the general adult population, it was also not required for pediatric use. Pediatric labeling does not contain a
similar warning even when there is no available pediatric data
showing that the drug is safe for use in kids and even when
known risks in that population exist. Thus, “the FDA permit[ed] drugs that are known to be risky to children [ ] contain
less precautious labeling than drugs tested in pregnant women
without any demonstration of risk.”378
The pregnancy labeling regulations also “focused exclusively on fetal (as opposed to maternal) risks from drug consumption.”379 This focus led to the result that “[w]arnings for
fetuses are much more protective than those for children; yet
pregnant women, who are also susceptible to increased drug
risks, received no warnings for their own safety.”380 By ignoring maternal harms, the FDA sent the clear message that fetal
risks were more important than maternal risks, and that “only
legitimate factors in drug consumption are fetal risk and
benefit.”381
And though pregnancy labeling was always required to recommend that pregnant women avoid drugs during pregnancy—which as noted, was an unnecessary, unusual, and
paternalistic requirement—the labeling “failed to present infor-
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mation on the risks associated with drug avoidance.”382 This is
a problem because women and fetuses can experience serious
complications when women avoid needed drugs in pregnancy.383 For instance, the recommendation to avoid anti-depressants in pregnancy can lead to premature birth, fetal
growth restriction, and increased drug and substance abuse in
pregnancy, among other complications, in addition to the
harmful effects for the women’s mental health.384 Thus, pregnant women were not given the information to evaluate the
fetal risks of avoiding drug use or the maternal risks associated
with either taking drugs or avoiding drugs. Finally, the pregnancy regulations were the only instance that the FDA required
the labeling to display animal data, which can be highly unreliable, even when data in pregnant women existed.385
After great criticism and decades of consideration, the FDA
finalized a rule that updated its labeling requirements for use
in pregnancy, which were phased in from 2015-2020.386 The
new regulations were an improvement: they eliminated the
drug categories, required the disclosure of risks affecting both
the pregnant woman and her fetus, required the risks of untreated medical conditions to be displayed, and removed the
blanket statement encouraging women to avoid drug use.387
Nevertheless, the modified regulations continue to rely on
animal data over objections from toxicologists, even low-quality
animal data.388
***
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Donley, supra note 370, at 73.
Id. at 57.
Id.
Id. at 73–75.
Id. at 49.
Id. at 76–78.
Id. at 78–80.
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In each of the cases described above, the FDA showed bias
and exceptionalism that harmed women’s health. Though each
one might seem like an isolated incident, their aggregate demonstrates that the agency has a blind spot when it comes to
women’s reproductive and sexual health. The agency has allowed the politics of contraception and abortion to override its
scientific mission. The mifepristone REMS is another instance
where the FDA is failing to follow its own mandate in the context of women’s reproductive health. As a result, it should be
removed.
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IV
REMOVAL OF THE REMS WILL TRANSFORM ABORTION
CARE
The mifepristone REMS is unnecessary, harmful, and not
supported by the statute. It reflects a history of bias at the FDA
related to women’s sexual and reproductive health. This Section first describes the effort to remove the REMS, which
started as a legal challenge under the Trump administration
but evolved into a direct request to the FDA under the Biden
administration. As this Article was coming to press, the FDA
announced that it will maintain the REMS, but remove the inperson dispensing requirement, suggesting that litigation may
still be necessary to fully dismantle the REMS. This Section
then explores how early abortion care is already being transformed by the removal of the in-person dispensing requirement, and how it can be further improved if the rest of the
REMS were also relinquished.
A. Paths Toward Removing the Mifepristone REMS

1. Constitutional Challenge
Historically, the most common challenge to abortion laws
was under the Due Process Clause—specifically, litigants argue that the law constitutes an undue burden under Planned
Parenthood v. Casey.390 An abortion law is unconstitutional
under this standard when it has “the purpose or effect of placing a substantial obstacle in the path of a woman seeking an
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389
Plaintiffs’ Memorandum of Law in Opposition to Defendants’ Motion for
Summary Judgment at 11–12, Chelius v. Azar, No. 17-cv-493 (D. Haw. Nov. 27,
2019).
390
505 U.S. 833, 836–38 (1992).
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Under the Trump administration, the only path to remove
the REMS was through litigation. In 2017, the ACLU launched
the first challenge attempting to invalidate the REMS. The
case, Chelius v. Azar,389 is ongoing—though currently stayed—
in the District of Hawaii. It is based on two separate legal
theories: first, that the mifepristone REMS creates an undue
burden in violation of the Fourteenth Amendment, and second,
that the agency acted arbitrarily and capriciously in instituting
the REMS, violating the Administrative Procedures Act. I
briefly explain the merits and weaknesses of these theories
below. I then explore how the Biden administration could remove the mifepristone REMS on its own.
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Id. at 877.
136 S. Ct. 2292, 2309 (2016).
393
Planned Parenthood of the Heartland, Inc. v. Iowa Bd. of Med., 865 N.W.2d
252, 254 (Iowa 2015).
394
“Laws prohibiting the ‘off-label’ use of abortion-inducing medication offer a
paradigm case of abortion exceptionalism.” Greenhouse & Siegel, supra note 270,
at 1447.
395
Planned Parenthood Arizona v. Humble, 753 F.3d 905 (9th Cir. 2014).
Though Humble was decided before Whole Woman’s Health, the Ninth Circuit had
already adopted a balancing test like the one relied on Whole Woman’s Health. Id.
In the Western District of Texas, a similar law was not invalidated because the
court did not use a balancing test. See Planned Parenthood of Greater Tex.
Surgical Health Servs. v. Abbott, 951 F. Supp. 2d 891, 905 (W.D. Tex. 2013).
396
June Med. Servs. v. Russo, 140 S. Ct. 2103, 2133-2142 (2020) (C.J. Roberts, concurring).
397
Id.
398
Id.
392
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abortion of a nonviable fetus.”391 In Whole Woman’s Health v.
Hellerstedt, the Court strengthened the undue burden standard by requiring that the law’s benefits outweigh its burdens.392 Thus, if the law has no benefits for women’s health,
then it would be unconstitutional because any burdens would
outweigh the nonexistent benefits. Relying on Whole Woman’s
Health or similar balancing tests, some lower courts have
found that laws similar to the REMS create an undue burden.
For instance, the Iowa Supreme Court in 2015 found a state
regulation requiring physicians to perform a physical exam and
be physically present when dispensing abortion medication unconstitutional under the state constitution, using a balancing
test.393 And the year before, the Ninth Circuit granted a preliminary injunction that prevented Arizona from requiring that
mifepristone be prescribed only according to its label, even
though off-label use is permitted and common for other
drugs,394 relying on a balancing test.395
But in June Medical v. Russo—the first abortion case after
Justice Kennedy retired—a majority of the Court did not sign
onto the balancing test from Whole Woman’s Health. Chief
Justice Roberts cast the fifth vote to overturn a restrictive Louisiana abortion regulation, but penned a separate concurrence
that effectively overruled the balancing test.396 He argued that
the balancing test was inconsistent with Planned Parenthood v.
Casey and that he would instead utilize a less rigorous version
of the undue burden standard in future cases.397 In his view,
the proper undue burden standard only looks to the law’s burdens and questions whether they are undue—not the law’s
benefits.398 In this view, it is irrelevant if the law benefits women’s health. Because Justice Roberts’s vote is now necessary
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to invalidate any abortion restriction, the reasoning in these
earlier cases, which relied on a balancing test, is inconsistent
with how a majority of the Supreme Court understands its
abortion precedent.
Since June Medical, the composition of the Supreme Court
has changed again. Justice Barrett replaced Justice Ginsburg,
moving the Court even further to the right. The impact of this
change was on display in ACOG v. FDA—a case concerning the
FDA’s failure to temporarily suspend the in-person dispensing
requirements of the mifepristone REMS during the COVID-19
pandemic. ACOG v. FDA was the first abortion case with Justice Barrett and was largely thought to signal the Court’s receptivity to both the Chelius case and abortion rights generally.
Before ACOG v. FDA reached the Supreme Court, the District of
Maryland had temporarily invalidated the in-person dispensing
requirements associated with the mifepristone REMS.399 The
district court, relying on Whole Woman’s Health’s balancing
test, before June Medical had been decided, found that:
Forcing a patient to travel in person to a hospital, clinic, or
medical office to pick up a pill she will swallow unsupervised
at home offers no medical benefit. And, in the present circumstances, any conceivable benefit is far outweighed by the
burdens it imposes on patients seeking care: needless exposure to the severe risks of illness and death associated with
COVID-19.400
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399
Order for Preliminary Injunction, ACOG v. FDA, No. 8:20-cv-01320-TDC
80 (D. Md. Jul. 13, 2020).
400
Id. at 25.
401
FDA v. ACOG, 141 S. Ct. 578 (2021). Justice Roberts relied on deference to
the agency, finding that the case did not concern the undue burden standard. Id.
(Roberts, C.J., concurring).
402
Id.
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Thus, the court found the in-person dispensing requirement to
create an unconstitutional undue burden.
The Supreme Court reversed this preliminary injunction.401 The majority did not issue reasoning; rather, the short
order only contained a brief concurrence by Chief Justice Roberts and a dissent by Justice Sotomayor that Justice Kagen
joined.402 In light of this outcome in ACOG v. FDA, it is hard to
imagine the Court reaching a different result in the Chelius
case, where the urgency of the pandemic is not at issue. “[B]y
allowing the FDA to enforce in-person requirements for
mifepristone during the pandemic, the Court heavy-handedly
insinuates that these same requirements would be acceptable
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in a non-pandemic world.”403 Perhaps more importantly, at a
time where the Supreme Court is expected to overturn or significantly limit the constitutional right to abortion in the near
future, a strategy that relies on this doctrine is not likely to be
successful, at least not before the Supreme Court.
2. Arbitrary and Capricious Challenge
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403
Jareb A. Gleckel & Sheryl L. Wulkan, Abortion and Telemedicine: Beyond
COVID-19 and the Shadow Docket, 55 UC DAVIS L. REV. ONLINE (forthcoming
2021), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3801124&
dgcid=EJournal_htmlemail_women,:gender:the:law:ejournal_abstractlink
[https://perma.cc/JLV2-LYZJ].
404
Metzger, supra note 309, at 869.
405
Id. at 899 (quoting Motor Vehicle Mfrs. Ass’n v. State Farm Mut. Auto. Ins.
Co., 463 U.S. 29, 43 (1983)).
406
INS v. Yang, 519 U.S. 26, 32 (1996).
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Given the current Supreme Court and the expected hostility it will have to future constitutional challenges to abortion
regulation, administrative law may be a more promising route.
As Gillian Metzger noted in 2007, “[a]dministrative law does not
offer the permanent protections of constitutional law and can
be quite deferential to administrative determinations. Nonetheless, administrative law’s requirements of explanation and
reasoned decisionmaking [sic] may in the end offer the greatest
protection against regulations that single out abortion for disfavored treatment.”404
There is solid evidence that the FDA has acted arbitrarily
and capriciously in subjecting mifepristone to a REMS. An
agency’s decision is generally considered arbitrary and capricious under the Administrative Procedures Act when the
agency “has relied on factors which Congress has not intended
it to consider, entirely failed to consider an important aspect of
the problem, offered an explanation for its decision that runs
counter to the evidence before the agency, or is so implausible
that it could not be ascribed to a difference in view or the
product of agency expertise.”405 Similarly, an agency acts illegally when “it announces and follows—by rule or by settled
course of adjudication—a general policy” and then commits “an
irrational departure from that policy (as opposed to an avowed
alteration of it).”406 In other words, the agency must follow its
own standards and fairly assess the evidence in applying those
standards.
In the Plan B litigation described above, the court invalidated the agency’s refusal to grant over-the-counter status to
Plan B for minor girls because it was treating Plan B exception-
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Tummino v. Hamburg, 936 F. Supp. 2d 162, 197–98 (E.D.N.Y. 2013).
Nat’l Res. Defense Council, Inc. v. SEC, 606 F.2d 1031, 1049 n.23 (D.C.
Cir. 1979).
409
Metzger, supra note 309, at 900.
410
Id.
411
See supra Part II.
412
Metzger, supra note 309, at 903–04 (“It is important not to oversell the
potential of administrative law as a constraint on abortion restrictions. While
offering a basis for searching scrutiny, administrative law also puts strong emphasis on deferring to agency expertise and policy choices, an emphasis reflected
(among other ways) in ostensibly deferential standards of review.”).
413
FDA v. ACOG, 141 S. Ct. 578 (2021) (Roberts, C.J., concurring).
408
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ally and not following its typical practices.407 The FDA’s history of bias and political involvement in reproductive health
decisions should increase the skepticism regarding its decision
here. “[W]here the agency has demonstrated undue bias towards particular [ ] interests,” “[m]ore exacting scrutiny” under
the APA is “particularly useful.”408 As Metzger noted, “[o]ften
what triggers greater scrutiny is judicial perceptions of perceived agency arbitrariness, expansion of power, or improper
influences.”409 She continues: “Inconsistent agency actions in
addressing abortion or reproduction issues similarly may trigger greater judicial scrutiny. Such inconsistency not only
raises the impression of arbitrary administrative action, but it
also suggests that the agency’s stated rationale is not what is
actually motivating its actions.”410
This Article highlights the evidence that the FDA irrationally departed from its standards when it issued the mifepristone REMS.411 There is a strong case to be made, therefore,
that the agency acted arbitrarily and capriciously. But there is
nevertheless reason to doubt that this line of attack would
ultimately prove successful, at least in the Supreme Court.
The outcome of any abortion case is likely to be influenced
by the values and ideologies of the judges hearing the case.
Though the ACOG v. FDA case did not involve an arbitrary and
capricious challenge, it is still unlikely that the Court would
affirm the agency’s decision to limit distribution during a pandemic but overrule the same decision under non-exigent circumstances. Second, overruling agency action can be a tall
task. Courts can highlight ample precedent that supports deference for agencies, especially for decisions that depend on an
interpretation of scientific data.412 In fact, Chief Justice Roberts’s concurrence in ACOG v. FDA used this reasoning to find
“that courts owe significant deference to the politically accountable entities with the ‘background, competence, and expertise to assess public health.’”413 This position may not be

43781-crn_107-3 Sheet No. 31 Side B

06/09/2022 09:20:03

\\jciprod01\productn\C\CRN\107-3\CRN302.txt

686

unknown

Seq: 60

CORNELL LAW REVIEW

4-JUN-22

13:48

[Vol. 107:627

popular with the rest of the conservative wing of the Court,
which has spent years attempting to weaken deference to administrative agencies,414 but it could nevertheless provide an
easy justification to allow the Court to maintain the mifepristone REMS while simultaneously appearing politically neutral.
Nevertheless, as explored below, this presumptive deference to the FDA would also make it difficult for a future antiabortion litigant to successfully challenge the Biden administration’s decision to release or significantly weaken the
mifepristone REMS after a reasoned decision.
3. Reconsideration Within the Agency
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414
Joshua Matz, The Imminent Demise of Chevron Deference?, TAKE CARE
(June 21, 2018), https://takecareblog.com/blog/the-imminent-demise-of-chevron-deference [https://perma.cc/7BSH-XZKM].
415
POLICY FOR CERTAIN REMS REQUIREMENTS DURING THE COVID-19 PUBLIC
HEALTH EMERGENCY, supra note 110, at 7 n.13.
416
Noah, supra note 59, at 573.
417
Bill Barrow & Seth Borenstein, Biden Says His Advisers Will Lead With
‘Science and Truth’, ABC NEWS (Jan. 18, 2021), https://abcnews.go.com/Technology/wireStory/correction-biden-science-story-75329323 [https://perma.cc/
X6FG-8KXT].
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Under the Trump Administration, litigation was the best
hope for invalidating the mifepristone REMS—there was no
chance that a Trump-appointed FDA Commissioner would
have allowed the agency to loosen an abortion restriction. Indeed, we saw the agency fight to keep the REMS in place during
the middle of a deadly pandemic when it was otherwise temporarily suspending REMS requirements for other medications.415 But with Biden’s 2020 victory, activists shifted their
approach to working directly with the agency to reevaluate the
REMS.
The president has historically only been able to affect abortion rights indirectly, but “mifepristone offer[s] the federal government a direct and significant occasion for affecting the
availability of abortion and, with it, the balance of power between pro-choice and pro-life forces.”416 By modifying the
mifepristone REMS, President Biden can give the progressive
women’s groups who supported his candidacy a win while also
promoting “science and truth” as he has promised.417 Moreover, first-trimester abortion is supported by a majority of Americans (sixty percent), and he could reasonably argue that
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Lydia Saad, Trimesters Still Key to U.S. Abortion Views, GALLUP (June 13,
2018), https://news.gallup.com/poll/235469/trimesters-key-abortionviews.aspx [https://perma.cc/DFG8-RDYW].
419
Mifeprex (mifepristone) Information, Food & Drug Admin (last updated
Dec. 16, 2021), https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information [https://
perma.cc/2VK8-5Z64].
420
FDA Letter, supra note 14.
421
Id. at 6-7.
422
Id. at 35.
423
Id. at 23-24.
424
Id. at 34-35.
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loosening the mifepristone REMS will reduce reliance on the
less popular second-trimester abortion.418
The Biden administration clearly had some of this in mind
when it announced on December 16, 2021 that it would permanently remove the in-person dispensing requirement. Though
the announcement on the website was bare bones,419 the
agency sent a letter to the American Association of Pro-Life
Obstetricians and Gynecologists outlining the reasons for its
decision.420 (That group had asked the agency to strengthen
the mifepristone REMS and make medication abortion more
difficult to access.) As noted above, the agency justified its
decision by relying on recent evidence and published data
clearly establishing the safety and efficacy of remote provision
of medication abortion.421 With that safety established, the
agency concluded that it must remove the requirement because
doing so “will render the REMS less burdensome to healthcare
providers and patients, and . . . the REMS will continue to
ensure that the benefits of mifepristone for medical abortion
outweigh the risks.”422 Nevertheless, the agency refused to remove the provider certification requirement or the patient
agreement form because no new data proved they were unnecessary;423 it similarly added a pharmacy certification requirement because it concluded that there was insufficient data to
suggest its safety and efficacy at retail pharmacies.424
Though the FDA’s decision to remove the in-person dispensing requirement was a step in the right direction, advocates should continue to put pressure on the agency to remove
the other REMS requirements. They can do this in a few ways:
First, reproductive health scholars can conduct research demonstrating that the other REMS requirements are unnecessary
for safety and efficacy and then ask the FDA to modify the
REMS based on that research. Though certainly worth the
investment, this research is time consuming and expensive,
meaning that this approach will likely take years. Second, ad-
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425
See Response to Opposition Comments filed by The Population Council,
Inc. and Danco Laboratories (Oct. 10, 2003), https://www.aaplog.org/wp-content/uploads/2002/08/ResponseToDanco10-03reRU-486.pdf [https://
perma.cc/U6J7-CAKY]; Letter from Ted Cruz, Senator, and Nineteen Other Senators to Stephen Hahn, Commissioner, FDA (Sept. 1 2020), https://
www.cruz.senate.gov/files/documents/Letters/2020.09.01%20--%20Pro-Life%
20Mifeprex%20Letter%20to%20FDA%20-%20FSV.pdf [https://perma.cc/L6Q987K6].
426
Letter to FDA Commissioner, supra note 425, at 2–3.
427
The arguments were made again in 2020 when Ted Cruz tried to get the
FDA to remove mifepristone from the market. Id.
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vocates can also continue the Chelius lawsuit and argue that
mifepristone does not meet the statutory criteria of a REMS. If
advocates win at the district court or circuit court level, the
FDA may decide not to appeal the decision and simply remove
the REMS in compliance with the lower court’s order, thereby
never asking the Supreme Court to weigh in.
It’s important to note that if the FDA does conclude that
the evidence supports removing the mifepristone REMS, it
would be difficult for anti-abortion activists to successfully
challenge that decision in litigation. Without a doubt, these
activists will sue the agency to try to get the decision overturned on administrative law grounds. But their lawsuit will be
unlikely to succeed. The FDA’s decision would be realigning
mifepristone with its treatment of similar drugs, ending the
kind of special treatment that gave rise to a strong arbitrary
and capricious challenge in Chelius. If the FDA is following the
proper procedures for releasing or modifying the REMS, and its
scientists conclude based on the best scientific evidence that
the release or modification of the REMS is justified, then it
would be difficult to argue that the scientific agency acted improperly by listening to scientists. Due to the high-profile nature of the decision, it will be vital for the FDA to ensure that its
decision follows the proper procedures perfectly and documents the scientific evidence. Any procedural misstep will
likely be used to invalidate the decision.
This is not to say it would be impossible for a motivated
court to find fault with the FDA’s decision to remove the
mifepristone REMS. Anti-abortion activists have argued since
the FDA approved mifepristone in 2000 that the drug is dangerous and should not only be restricted, but entirely removed
from the market.425 They have also suggested that the Clinton
administration acted politically and unusually by seeking out a
sponsor to support a New Drug Application for mifepristone.426
These arguments will likely get recycled in litigation about the
mifepristone REMS.427
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But just as precedent on judicial deference to administrative agencies would harm abortion rights activists in the Chelius lawsuit, it would similarly harm anti-abortion activists in a
lawsuit challenging the removal or modification of the
REMS.428 It is not the role of the courts to review scientific
evidence and decide whether a drug’s risks can only outweigh
its benefits without a REMS—even a conservative judge would
recognize that such a scientific judgment should be made by
the agency to which it was delegated. Rather, the courts’ role is
to consider whether the agency’s decision was arbitrary and
capricious. It is particularly noteworthy that Chief Justice
Roberts relied on deference to the FDA in his concurrence overturning the preliminary injunction in ACOG v. FDA.429 This
could signal how he might be inclined to vote if the opposite
case reached the Supreme Court. And importantly, even if a
court were to find a procedural flaw that warranted a reversal
of the agency’s decision, the agency would be free to reissue the
decision, correcting the flaws identified by the court.
B. The Future of Abortion Care Without the Mifepristone
REMS
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428
It is true that the Supreme Court in Gonzales v. Carhart showed a willingness to ignore the bulk of scientific evidence about when an abortion procedure
could be medically necessary because a minority view contradicted it. Gonzales v.
Carhart, 550 U.S. 124, 163 (2007) (“The Court has given state and federal legislatures wide discretion to pass legislation in areas where there is medical and
scientific uncertainty.”). But that precedent relied on the Court deferring to the
fact-finding of conservative states, which relied on that minority view, not overriding a fact-finder—in this case the agency—with its own judgment on the science.
429
141 S. Ct. 578, 578–79 (2021) (Roberts, C.J., concurring).
430
Rachel K. Jones et al., Medication Abortion Now Accounts for More Than
Half of All US Abortions (Feb. 2022), https://www.guttmacher.org/article/2022/
02/medication-abortion-now-accounts-more-half-all-us-abortions.
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Removing the mifepristone REMS has the power to transform early abortion care. Already, the removal of the in-person
dispensing requirement has created possibilities that were
unimaginable five years ago—namely, an early abortion
through telehealth without ever leaving one’s home. And these
innovations led to medication abortion becoming, for the first
time, the majority (54%) of all abortions in 2020.430 But these
benefits will not be felt everywhere. Some states have their own
laws that will continue to burden medication abortion provision even if the federal policy disappears. Nineteen states, for
instance, either require medication abortion to be distributed
in the presence of a physician or ban the use of telemedicine for

43781-crn_107-3 Sheet No. 33 Side B

06/09/2022 09:20:03

\\jciprod01\productn\C\CRN\107-3\CRN302.txt

690

unknown

Seq: 64

CORNELL LAW REVIEW

4-JUN-22

13:48

[Vol. 107:627

abortion.431 More states are likely to pass similar laws in the
next few years.432 As a result, the FDA’s removal of the inperson dispensing requirement will not help patients in these
states.
In the remaining thirty-one states, however, removing the
in-person dispensing requirement will lead to an enormous expansion of access. Many of these changes have already begun.433 The COVID-19 pandemic transformed remote abortion
care from a distant dream to a current reality.434 After the
District of Maryland temporarily suspended the in-person dispensing requirement, a variety of start-ups launched, including Abortion on Demand, Hey Jane, Choix, and Just the Pill,
which created “virtual clinics” that provide remote abortion
care.435 Some of these organizations are innovating abortion
care, like sending the abortion medication in a care package
that includes herbal tea and anti-nausea medication, and most
have significantly cut the cost of early abortion by hundreds of
dollars.436 More traditional abortion clinics also began mailing
abortion medication after meeting with patients via
telemedicine.437 As a result, telemedicine is quickly becoming
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431
Medication Abortion, G UTTMACHER INST. (May 1, 2021), https://
www.guttmacher.org/state-policy/explore/medication-abortion [https://
perma.cc/4JRF-NNT5].
432
See Alice Miranda Ollstein & Darius Tahir, Will At-Home Abortions Make
Roe V. Wade Obsolete?, POLITICO (updated March 21, 2021), https://
www.politico.com/news/2021/03/20/abortion-pills-telemedicine-477234
[https://perma.cc/6QJX-GPQV].
433
See Chong et al., supra note 189, at 2 (noting that demand for the Gynuity
trial tripled during the pandemic); Ruth Reader, The Pandemic Sparked The Rise
of Tele-Abortion. Is it Here to Stay?, FAST COMPANY (Oct. 2, 2020), https://
www.fastcompany.com/90550536/telehealth-abortion-pill-supreme-court-ruling [https://perma.cc/WE8K-G74W]; Carrie N. Baker, How Telemedicine Startups
Are Revolutionizing Abortion Health Care in the U.S., MS. MAG. (Nov. 16, 2020),
https://msmagazine.com/2020/11/16/just-the-pill-choix-carafem-honeybeehealth-how-telemedicine-startups-are-revolutionizing-abortion-health-care-inthe-u-s/ [https://perma.cc/ZGE8-8L5Q].
434
See Reader, supra note 433 (noting that these start-ups started offering
remote abortions after the District of Maryland suspended the in-person dispensing requirements); Baker, supra note 433.
435
Reader, supra note 433.
436
Susan Rinkunas, A Bitter Pill, MARIE CLAIRE (Jan. 13, 2021), https://
www.marieclaire.com/politics/a35203155/pandemic-abortion-telemedicine/
[https://perma.cc/MXZ6-T9XW].
437
See id. (noting that Whole Woman’s Health is offering remote appointments); see also PPMW Now Offering Medication Abortion At-Home Services, PLANNEDPARENTHOOD.ORG. (Sept. 10, 2021), https://www.plannedparenthood.org/
planned-parenthood-metropolitan-washington-dc/press-room/ppmw-now-offering-medication-abortion-at-home-services [https://perma.cc/3NQT-5T38] (noting that Planned Parenthood of Metropolitan Washington, DC started offering
telemedicine).
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the norm for early abortion care in states that allow it.438 This
trend is unlikely to change once the pandemic ends: “[t]he genie’s out of the bottle. And once the genie is out of the bottle,
it’s really hard to get it back in.”439
Telemedicine for early abortion care means that patients
would no longer need to travel to clinics to end a pregnancy in
the first ten weeks.440 As noted in subpart I.C, this would
immediately improve access by reducing the cost and logistical
burdens associated with travel, especially for those who live
hundreds of miles from the nearest clinic.441 This will especially benefit rural women, who must travel the farthest, and
poor women, who are least able to afford the costs associated
with travel.442 Perhaps even more importantly, remote abortion care itself is also less expensive—almost half the price of
clinic-based care.443 Given that most patients pay for abortion
out of pocket444 and half of those needing an abortion live in
poverty,445 this benefit will be very impactful for all abortion
patients.
Another huge advantage of telemedicine is that patients
would no longer need to endure the stigma and violence associated with abortion clinics.
Encountering protestors who intimidate, shame, harass, and
harangue people who are doing nothing more than entering a
medical clinic is normal around the country for patients trying to get an abortion. In no other areas of medicine are
patients subjected to this kind of harassment just for walking
into a doctor’s office.446
R

Rinkunas, supra note 436.
Mounting evidence suggests that medication abortion is safe and effective
through twelve weeks, and the mifepristone label may eventually be changed to
extend the timing of its use. Nathalie Kapp et al., Medical Abortion in the Late First
Trimester: A Systematic Review, 99 CONTRACEPTION 77, 77 (2019); What Will Happen If You Do An Abortion With Pills After The First 12 Weeks?, WOMENONWEB,
https://www.womenonweb.org/en/page/573/what-will-happen-if-you-do-anabortion-with-pills-after-the-first-12 [https://perma.cc/FG6F-4EWV] (last visited
Mar. 23, 2021).
441
See supra subpart I.C.
442
See supra subpart II.B.
443
Rinkunas, supra note 436.
444
How do Women Pay for Abortions, GUTTMACHER INST. (2013),https://
www.guttmacher.org/sites/default/files/graphics/infographics/
HowDoWomenPay-740.pdf [https://perma.cc/EP7F-9LBF].
445
Sabrina Tavernise, Why Women Getting Abortions Now Are More Likely to
Be Poor, N.Y. TIMES (July 9, 2019), https://www.nytimes.com/2019/07/09/us/
abortion-access-inequality.html [https://perma.cc/4273-Q5GQ].
446
COHEN & JOFFE, supra note 123, at 114.
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Baker, supra note 433 (describing remote abortion as the new standard of
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Chong et al., supra note 189, at 2.
COHEN & JOFFE, supra note 123, at 119.
449
See Yvonne Lindgren, The Doctor Requirement: Griswold, Privacy, and AtHome Reproductive Care, 32 CONST. COMMENT. 341, 358–64 (2017) (describing the
privacy benefits associated with abortion at home); see also infra Part IV (describing how telehealth can improve abortion access and the abortion experience).
450
Anti-Abortion Violence, NARAL PRO-CHOICE AM., https://www.prochoicea
merica.org/issue/anti-abortion-violence/ [https://perma.cc/XT6Q-32ET].
451
COHEN & JOFFE, supra note 123, at 114–15.
452
See Cohen & Connon, supra note 130, at ix–x (noting that “partly because
abortion providers are not safe, there are very few abortion providers in the United
States”).
448
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There is a recent rise of picketing and obstructing abortion
facilities: “the National Abortion Federation’s 2019 annual report on violence and disruption statistics documented 3,387
incidents of obstructing facilities (up from 3,038 in 2018), and
123,228 incidents of picketing (up from 99,409 in 2018).”447 In
addition to traditional harassment, protestors have recently
started posing as clinic staff to try to trick patients into giving
them their names so that they can publicly disclose their abortions and shame them online; protesters have also started recording women walking into clinics, often streaming them on
Facebook Live, to further shame them on social media.448 Women using telemedicine can avoid this stressor entirely and
end their pregnancy in the privacy of their homes.449 This shift
could radically reduce the public stigma associated with abortion care.
Furthermore, the less abortion is tied to physical locations,
the harder it will become for extremists to target and attack
providers and clinics. Abortion providers have been murdered,
threatened, and physically attacked simply for providing abortion, and their clinics have been bombed, broken into, and
defaced.450 Concentrating all abortion care in certain locations
like clinics makes it easy for protesters and extremists to target
providers and patients. For instance, hospitals that provide
abortions experience almost no protests or violence—abortions
are only a tiny fraction of the care hospitals provide, and it
would be practically impossible for the protesters to determine
which patients and providers at the hospital were there for
abortions.451 If early abortion occurred online through
telemedicine or moved to physician offices, it would be similarly
difficult to target doctors and offices providing that care. And
by making it safer and less stigmatizing for providers to offer
early abortion care, more physicians would likely be willing to
provide it.452
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Rinkunas, supra note 436.
Given that the majority of abortions occur in the first trimester, see SecondTrimester Abortion, ACOG (June 2013), https://www.acog.org/clinical/clinicalguidance/practice-bulletin/articles/2013/06/second-trimester-abortion [https:/
/perma.cc/M62M-UK9R], when all abortion care occurred in clinics, the majority
of clinic-based care was in the first trimester. However, this would change if
telemedicine “skim[s] off all of the early abortions” from clinics. Rinkunas, supra
note 436.
455
Rinkunas, supra note 436.
456
See Later Abortion, GUTTMACHER INST. (Nov. 13, 2019), https://
www.guttmacher.org/evidence-you-can-use/later-abortion [https://perma.cc/
JPR6-4YTP].
457
Lindgren, supra note 449.
454
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Though this de-linking of early abortion from physical
spaces has many positive implications for early abortion care,
clinics would still be necessary for surgical abortions after ten
weeks.453 Given that these later abortions tend to be more
controversial, one potential consequence could be that violence
at abortion clinics actually increases—all of a sudden, the majority of clinic-based abortion care could flip from first-trimester abortions to second-trimester abortions.454 Thus, while
patients and providers involved with early abortion care could
see a real improvement in their safety and wellbeing, those
needing and providing later abortions might feel even more
threatened. Clinics are also expected to struggle financially if
new, virtual clinics reduce demand for their services, which
could lead to more clinic closures, even in states with abortion
friendly laws.455 This is a serious concern given that it is already difficult for women to find a clinic that offers secondtrimester abortion care.456 In other words, the removal of the
REMS will improve the experience and availability of early
abortion but could have the opposite effect on abortion after
ten weeks.
The move away from clinic-based care will also make it
harder to regulate abortion spaces. Clinics not only attract
violence and harassment but also legislative attention. “Abortion opponents have taken aim at stand-alone clinics, describing them as ‘abortion mills’ and seeking to undermine the
legitimacy of abortion providers.”457 This perspective ignores
the reality that abortion is segregated into clinics because of
laws like the mifepristone REMS that have isolated abortion
outside of traditional healthcare. Nevertheless, states have
historically attempted to regulate the physical space within
abortion clinics to the extent that compliance is difficult or
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458
See Targeted Regulation of Abortion Providers, GUTTMACHER INST. (May 1,
2021), https://www.guttmacher.org/state-policy/explore/targeted-regulationabortion-providers# [https://perma.cc/D3SK-XLG6].
459
Id.
460
See Lindgren, supra note 449, at 358–64 (describing the privacy benefits
associated with medication abortion in the home).
461
See Elizabeth Nash, Unprecedented Wave of Abortion Bans is an Urgent
Call to Action, GUTTMACHER INST., https://www.guttmacher.org/article/2019/05/
unprecedented-wave-abortion-bans-urgent-call-action [https://perma.cc/GS5QR38V] (updated May 31, 2019); Elizabeth Nash et al., State Policy Trends 2019: A
Wave of Abortion Bans, But Some States Are Fighting Back, GUTTMACHER INST.
(Dec. 12, 2019), https://www.guttmacher.org/article/2019/12/state-policytrends-2019-wave-abortion-bans-some-states-are-fighting-back [https://
perma.cc/JS43-LK4D].
462
Mary Ziegler, This Could Be the Case That Takes Down Roe v. Wade, CNN
(May 18, 2021), https://www.cnn.com/2021/05/17/opinions/abortion-mississippi-supreme-court-dobbs-v-jackson-womens-health-ziegler/index.html
[https://perma.cc/688L-PRSS].

43781-crn_107-3 Sheet No. 35 Side B

impossible.458 For instance, “9 states specify the size of the
procedure rooms,” “8 states specify corridor width,” and “8
states require abortion facilities to be within a set distance from
a hospital.”459 When abortion is happening entirely online and
in the privacy of one’s home, there are no physical spaces to
regulate.460 This is not to say that antiabortion legislatures will
be unable to regulate abortion provided online—or simply ban
it as many states have done—but it does undercut one of their
common strategies over the past few decades.
Unfortunately, the states with the fewest brick-and-mortar
clinics are also those most likely to have laws that prevent
telemedicine for abortion. Thus, in the states where remote
abortion access could be the most beneficial because there are
the fewest clinics and greatest harassment at those clinics, it
will likely be prohibited. As a result, removing the mifepristone
REMS will accelerate the existing polarization of abortion access across state lines. States in the South and Midwest already limit abortion access as much as possible and won’t see
much change in their legal abortion model after the REMS is
removed; northern and coastal states, on the other hand,
which have recently sought to codify and expand abortion protections, will see dramatic improvement in early abortion access without the in-person dispensing requirements.461
The Supreme Court’s upcoming abortion decisions are expected to further intensify polarization by allowing conservative
states to decrease (and perhaps eliminate) abortion access. In
May 2021, the Court announced that it would hear a case that
is a direct challenge to the viability standard in Casey.462 The
case, Dobbs v. Jackson Women’s Health Organization, concerns
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whether a state can ban abortion starting at fifteen weeks, long
before a fetus is viable.463 With Justices Barrett and Kavanaugh replacing Justices Ginsburg and Kennedy, there is a
genuine fear that the constitutional right to abortion may become a relic of a different era.464 If the Supreme Court does
move to further limit or overturn Roe, states will have even
more power to determine their own abortion regulations, and
nearly half are expected to ban all or most abortions.465 These
bans would disproportionately and significantly harm poor women, rural women, and women of color living in antiabortion
states, who would struggle to afford the high cost of interstate
travel to access care.466 Nevertheless, women living in the remaining states will continue to enjoy all the benefits of expanded access to early abortion that came from removing the
in-person dispensing requirement. As a result, the removal of
the mifepristone REMS has the power to transform and improve abortion access in parts of the country even if the constitutional right to abortion falls.
The states that have their own limits on medication abortion—or, if Dobbs allows, even ban abortion completely—will
still see ripple effects associated with greater abortion access in
other parts of the country. One of these effects is an increase in
illegal, self-managed abortion everywhere. Though illegal abortion conjures up images of the back-alley abortions from generations ago, self-managed abortion in today’s world is very
different. It essentially involves women taking the same FDAapproved medications, but purchased outside of the traditional
healthcare setting, and often without the help of a
physician.467
Many abortion rights activists believe self-managed abortion will become the future of abortion care, especially if Roe is
overturned or dramatically weakened.468 Already, self-man463
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Elizabeth Nash & Lauren Cross, 26 States Are Certain or Likely to Ban
Abortion Without Roe: Here’s Which Ones and Why, GUTTMACHER INST. (Oct. 2021),
https://www.guttmacher.org/article/2021/10/26-states-are-certain-or-likelyban-abortion-without-roe-heres-which-ones-and-why [https://perma.cc/YAV6P9EX].
466
Megan K. Donovan, In Real Life: Federal Restrictions on Abortion Coverage
and the Women They Impact, 20 GUTTMACHER POL. REV. 1, 5–6 (2017).
467
See Donovan, supra note 466, at 44.
468
See, e.g., How Activists Can Prepare for a Post-Roe World, REPROACTION
(Sept. 21, 2018), https://reproaction.org/resource/how-activists-can-preparefor-a-post-roe-world/ [https://perma.cc/785J-2Y5L] (describing how medication
abortion has been used in other countries where abortion is criminalized). In
464
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2021, the Supreme Court agreed to hear a case that would directly challenge Roe
v. Wade. See Ziegler, supra note 462.
469
Abigail R. A. Aiken et al., Demand for Self-Managed Medication Abortion
Through an Online Telemedicine Service in the United States, 110 AM. J. PUB.
HEALTH 90, 90 (2020).
470
Id. at 92, 94.
471
See David S. Cohen, Greer Donley, & Rachel Rebouche, The New Abortion
Battleground (draft manuscript on file with author) (describing the complex legal
issues that will challenge state enforcement of abortions laws related to out-ofstate conduct); Rachel Rebouche, The Public Health Turn in Reproductive Rights,
78 WASH. & LEE L. REV. 1355, 1400, n.220 (2021) (noting, and citing scholarship
for the proposition, that in the context of interstate travel for an abortion at a
clinic, “there are mixed views about whether states could limit residents from
seeking abortion outside of state lines”).
472
Rebouche, supra note 471, at 40; Gleckel & Wulkan, supra note 403, at
15–16.
473
The Plan C Guide to Abortion Pills, Plan C (last visited Nov. 7, 2021),
https://www.plancpills.org/guide-how-to-get-abortion-pills#find-pills [https://
perma.cc/FXR2-RZRG].
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aged abortion has grown as abortion became increasingly difficult to access in parts of the country,469 with a greater
incidence in states with harsher abortion restrictions.470 But
as mifepristone becomes easier to access in a majority of states
because the FDA has loosened its unnecessary restrictions,
women in conservative states will likely be able to obtain the
drug more easily, albeit, illegally, from other states (instead of
relying on international pharmacies, as they do now). Women
in these restrictive states could meet with an out-of-state provider by telemedicine who mails them the medication directly
or calls the prescription into an out-of-state, mail-in pharmacy
that ships them the drug. Not only would this practice be
almost impossible to police because the abortion would occur
in a private setting, but it might also be legally difficult to
restrict.471
Even if abortion providers continued to only ship abortion
medication to addresses within their state, where doing so was
legal, one could easily imagine a world in which a patient in a
restrictive state lies about their location and gives the provider
an address of a friend, family member, or ally within that provider’s state lines, who would then ship the out-of-state patient
the drug once it arrives.472 Plan C, an organization that helps
women find abortion medication, has detailed instructions on
its website for creating a temporary address in a state that
allows remote abortion access so that a patient in an abortionrestricting state could visit a virtual clinic, provide that temporary address, and then have the pills forwarded to their home
address without ever leaving their house.473 Furthermore, remote abortion care makes traveling out of state for abortion
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easier because women can have the medication mailed to a
post office near the state line instead of needing to travel to a
clinic within that state.474
Though a healthcare provider’s involvement is still the gold
standard for abortion care, self-managed abortion can be done
safely. According to the World Health Organization, there are
three components to self-managed abortion without the involvement of a provider (sometimes referred to as self-sourced
abortion): “[1] self-assessing eligibility; [2] managing the
mifepristone and misoprostol medication without direct supervision of a health care provider; and [3] self-assessing completeness of the abortion process using pregnancy tests and
checklists.”475 Evidence endorsed by the WHO suggests that
the latter two components can be done safely.476 Even under
the REMS, most women already take the abortion medication
drugs at home and assess the abortion’s completion on their
own with pregnancy tests; as a result, it makes sense that
women do not need a doctor’s direct involvement during those
phases of the abortion, so long as they have “a source of accurate information and access to a health-care provider should
they need or want it at any stage of the process.”477
However, until very recently, researchers have had questions about the safety of the first component—i.e., how accurately women can assess their own eligibility. This selfassessment primarily relies on a woman’s ability to accurately
assess the gestational age of her pregnancy, which evidence
suggests that most women can accurately do.478 As mentioned above, only 1% of medication abortion patients who
were certain that their last missed period had started less than
seventy-eight days ago were proven wrong on ultrasound.479
Many abortion patients, however, will not be certain of their
last missed period, and for them, self-assessment will be more
challenging. As noted, there have been incidences of self-managed abortion well into the second trimester that led to medical
emergencies.480 Furthermore, there are other eligibility questions related to risk factors, like whether a woman could have a
rare ectopic pregnancy, which is contraindicated for mifepristone, or a negative blood type, which might require an addi-
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tional medication to protect her future fertility.481 Fewer
women know their blood type and only an ultrasound can diagnose an ectopic pregnancy.482
The traditional medication abortion model based on clinic
care eliminated these risks by recommending that all women
get blood work and an ultrasound before receiving the medication abortion.483 The ultrasound could rule out ectopic pregnancy and verify the length of pregnancy, and the blood work
could identify women who are Rh negative and might need
additional medication. But the pandemic catalyzed a paradigm
shift that is altering the early abortion model that had been
used for decades.484 The zeitgeist now prefers “no touch abortions,” where most women can obtain abortion care without
any in-person testing, unless it is medically indicated.485 Not
only does this model remove even more logistical burdens associated with care, but it also reduces the cost of the abortion,
making abortion even more accessible.486
More recent data suggests that these extra tests are unnecessary. For instance, recent studies have shown that for women who are Rh negative, antibodies may not develop to a
pregnancy in the first ten weeks and therefore the additional
medication would not be necessary.487 And because ectopic
pregnancy often comes with symptoms like bleeding or pain,
ultrasound could be reserved for women experiencing those
symptoms.488 The virtual clinics described above are already
offering no-touch abortions, and even traditional clinics are
R
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Id. at 364.
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Id. at 361.
484
Id. (“Across all fields of medicine, changes in practice models are occurring
rapidly. For patients seeking abortion, urgent modifications of current protocols
are needed to ensure that patients can continue to obtain this time sensitive
treatment while limiting transmission of infection by maintaining distance between and among patients and providers.”); Chong et al., supra note 189, at 2, 4
(noting that “[e]xperts have advocated for adoption of no-test medication abortion,” but that “[i]ndividuals were required to obtain a pre-abortion ultrasound or
pelvic exam” to participate in the study, even though 52% of sites did not enforce
the requirement).
485
See Telehealth Care for Medication Abortion Protocol, REPROD. ACCESS
(May 2021), https://www.reproductiveaccess.org/wp-content/uploads/2020/
03/03-2020-no-touch-MAB.pdf [https://perma.cc/X5W6-CA38].
486
Baker, supra note 433; see Chong et al., supra note 189, at 4 (noting that
“[m]onths with high enrollment were also months in which large percentages of
abortions occurred without screening ultrasounds”).
487
Alice Mark et al., Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion
Federation’s Clinical Policies Committee, 99 CONTRACEPTION 265, 266 (2019).
488
Raymond et al., supra note 135, at 363–34.
482

43781-crn_107-3 Sheet No. 37 Side B

481

43781-crn_107-3 Sheet No. 38 Side A

06/09/2022 09:20:03

\\jciprod01\productn\C\CRN\107-3\CRN302.txt

2022]

unknown

Seq: 73

MEDICATION ABORTION

4-JUN-22

13:48

699

moving in this direction by altering their protocols so that women never need to set foot in a healthcare facility to receive an
abortion.489 Two very recent studies, one in England490 and
one in the United States,491 show that no touch medication
abortions are safe and effective. As a result, it appears that
even when it comes to self-assessment of eligibility, a physician’s involvement may not be required except when women
are unsure of their last period or experiencing symptoms of
ectopic pregnancy. Scholars have similarly started criticizing
as paternalistic the doctrinal link that has woven physician
involvement into the right to abortion.492
Nevertheless, as described in Part II, there will still be serious legal risks associated with self-management given the fact
that many states have enforced a variety of laws against pregnant women who self-induce an abortion.493
[T]here are 7 states with laws directly criminalizing self-induced abortions, 10 states with laws criminalizing harm to
fetuses that lack adequate exemptions for the pregnant person, and 15 states with criminal abortion laws that have been
and could be misapplied to people who self-induce. There are
also a variety of laws that have been used when other
grounds are unavailable, including those governing the disposal of human remains and concealment of a birth.494
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Baker, supra note 433 (describing remote abortion as the new standard of
care); Carrie N. Baker, No-Test Medication Abortion Increases Safety and Access
During COVID-19, MS. MAG. (May 13, 2020), https://msmagazine.com/2020/05/
13/no-test-medication-abortion-increases-safety-and-access-during-covid-19/
[https://perma.cc/9N7Q-EHDY] (interviewing a provider who is already using the
new protocol).
490
A.R.A. Aiken, P.A. Lohr, J. Lord, N. Ghosh & J Starling, Effectiveness,
Safety and Acceptability of No-Test Medical Abortion (Termination of pregnancy)
Provided via Telemedicine: A National Cohort Study, 128 INT’L J. OBSTET. &
GYNAECOL. 1464, 1470 (2021).
491
Ushma D. Upadhyay et al., Outcomes and Safety of History-Based Screening for Medication Abortion A Retrospective Multicenter Cohort Study, JAMA INTERNAL MEDICINE (March 2022), file:///Users/DONLEY/Downloads/jamainternal_up
adhyay_2022_oi_220007_1647267379.10073.pdf.
492
See Lindgren, supra note 457, at 3.
493
See supra Part II.
494
Self-Managed Medication Abortion, supra note 216, at 45.
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Motivated prosecutors have found a variety of arcane legal avenues to criminalize those who self-manage, and if abortion becomes illegal in certain states, prosecuting abortion will
become easier. Though it has historically been politically undesirable to prosecute patients for abortions, and laws typically
prefer to criminalize providers, this might change if providers

43781-crn_107-3 Sheet No. 38 Side B

06/09/2022 09:20:03

\\jciprod01\productn\C\CRN\107-3\CRN302.txt

700

unknown

Seq: 74

CORNELL LAW REVIEW

4-JUN-22

13:48

[Vol. 107:627

are out of state and harder to control.495 On the other hand, as
self-management becomes more commonplace and organized,
women can be counseled about how to avoid detection, even
when experiencing side-effects and risks that require medical
care.496 Because there is no discernable difference between an
abortion by medication and miscarriage, women who need
medical care can simply show up to a hospital claiming to be
experiencing natural fetal loss.497
Though self-managed abortion is likely to increase in antiabortion states, removing the in-person dispensing requirement will likely reduce self-management in abortionsupportive states. Self-management will become less desirable
when it is easy to access medication abortion from a U.S. provider while still ending the pregnancy in the privacy of one’s
home, avoiding the harassment, travel, and obstacles associated with clinic-based care, and the legal risks associated with
self-management.498 And as argued above, the very possibility
of self-management with abortion care should encourage the
FDA to release the REMS in its entirety to encourage women to
obtain care through a doctor given that self-management is
already an option for American women.499 And the FDA may
be worried about the fact that many women attempt to self-
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495
See Cohen, Donley & Rebouche, supra note 471. Georgia’s recent abortion
law would start subjecting women who get illegal abortions to criminal prosecution, including life imprisonment and the death penalty. Mark Joseph Stern,
Georgia Just Criminalized Abortion. Women Who Terminate Their Pregnancies
Would Receive Life in Prison, SLATE (May 7, 2019), https://slate.com/news-andpolitics/2019/05/hb-481-georgia-law-criminalizes-abortion-subjects-women-tolife-in-prison.html [https://perma.cc/PSK2-PJ86].
496
So long as the abortion is in the first trimester, women should be able to
seek medical care by indicating that they were suffering from a miscarriage, not
an abortion. Reader, supra note 433.
497
Though this pretense will protect many women, it is becoming more common for zealous prosecutors to prosecute women experiencing pregnancy loss due
to the perception that the woman was attempting to terminate the pregnancy.
See, e.g., The Editorial Board, When Prosecutors Jail a Mother for a Miscarriage,
N.Y. TIMES (Dec. 28, 2018), https://www.nytimes.com/interactive/2018/12/28/
opinion/abortion-pregnancy-pro-life.html [https://perma.cc/TY69-LHJA]. I suspect these instances will continue to grow as illegal abortion becomes more common, harming women—especially poor women and women of color—experiencing
abortion, miscarriage, and stillbirth.
498
See Aiken et al., supra note 469, at 93 (describing the various reasons
women sought self-managed abortion, including the desire for privacy and the
burdens associated with clinics); A Roadmap for Research on Self-Managed Abortion in the United States, GYNUITY HEALTH 1 (Aug. 2018), https://ibisreproductivehealth.org/sites/default/files/files/publications/US%20research
%20roadmap%20self%20managed%20abortion.pdf [https://perma.cc/G6S38L4U]; Daniel Grossman, et al., Self-Induction of Abortion Among Women in the
United States, 18 REPROD. HEALTH MATTERS 136, 144 (2010).
499
See supra Part II.
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Ushma D Upadhyay, Alice F. Cartwright, Daniel Grossman, Barriers to
abortion care and incidence of attempted self-managed abortion among individuals searching Google for abortion care: A national prospective study, 106 Contraception, 49, 49 (2022).
501
Medication Abortion, supra note 431.
502
Self-Managed Medication Abortion, supra note 216, at 43–44.
503
COHEN & JOFFE, supra note 123, at 223.
504
Mifeprex REMS Study Group, supra note 35, at 792.
505
See Cohen & Connon, supra note 130, at ix–x (noting that “partly because
abortion providers are not safe, there are very few abortion providers in the United
States”).
506
Self-Managed Medication Abortion, supra note 216, at 43; Mifeprex REMS
Study Group, supra note 35, at 792.
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manage in less safe ways—with physical trauma or ineffective
supplements and herbs.500
Beyond the in-person dispensing requirement, if the FDA
removed the rest of the REMS, the agency’s abortion exceptionalism would cease, and patients would see additional benefits
in accessing early abortion. Patients in states without their
own prohibitions could obtain a prescription for medication
abortion from any willing doctor and pick up the medication in
any pharmacy.501 Doctors in these states would still need to be
educated about, and act in compliance with, local abortion
laws before prescribing mifepristone, and some providers and
pharmacists would refuse to prescribe or dispense mifepristone based on conscience,502 but abortion would immediately
become less siloed. And the more integrated abortion becomes
in traditional healthcare, the more normal and less stigmatized
it will be.
Primarily, removing the provider certification requirement
will lead to an increase in physicians offering medication abortion.503 No longer would providers need to opt into a prescribing system or identify as an abortion provider—they would
simply provide early abortions to their patients when they need
them. This would reduce the fear that the certified provider list
could be leaked after a data breach, exposing all the providers
on the list to harassment and violence.504 Similarly, now that
physicians can provide early abortion care from their home
offices or via telemedicine (i.e., not always at clinics), they
might similarly feel safer.505 And if all pharmacies could similarly dispense the drug without certification, providers would
no longer need to deal with the logistical burdens associated
with dispensing the drug in house or establishing a relationship with a “certified pharmacy.”506 Given that 87% of counties
in the United States lack an abortion provider, and 34% of
women of reproductive age live in a county without an abortion
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Data Center, GUTTMACHER INST., https://data.guttmacher.org/states/table?state=US&topics=71+72+73&dataset=data [https://perma.cc/HV8J-JFJT].
508
Nash & Cross, supra note 465.
509
Ashely Hacket, After Texas’ abortion ban, some groups have seen increased
demand for abortions in Minnesota, Minn Post (Nov. 19, 2021), https://
www.minnpost.com/health/2021/11/texas-abortion-ban-has-increased-demand-for-legal-abortions-in-minnesota-and-it-might-just-be-the-beginning/
[https://perma.cc/2EW8-GCMQ](““However,” Rierson said, “We’re overwhelmed
now. And if Roe falls, the combination of state level restrictions [in other states]
and the lack of providers here means that we’re not going to be able to meet the
need if it’s federally overturned.”)
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provider,507 increasing the number of providers could reduce
the burden on existing abortion providers and improve access
to abortion generally.
If the Supreme Court overrules Roe v. Wade, and roughly
half the states ban abortion, increasing the number of abortion
providers in abortion-supportive states will be urgently important.508 In this scenario, abortion providers in half the country
will be responsible for providing all U.S. abortions. Already,
SB8—a Texas law that essentially bans abortions after six
weeks in our country’s second most populous state—have
pushed providers to the brink of their capacity, even in distant
states like Minnesota.509 If half the country bans abortion, the
entire system will experience immense strain, delaying care for
everyone. To the extent the remaining states can increase the
number of providers offering early abortion care, it will free up
surgical abortion providers to focus their expertise on those
needing abortions past ten weeks.
Removing the mifepristone REMS will also have an impact
on miscarriage management. As mentioned above, recent research has suggested that the same combination of medications used for abortion (mifepristone and misoprostol) is more
effective at treating a missed or incomplete miscarriage than
the current protocol, which only involves misoprostol.510 Without the mifepristone REMS, any provider could start prescribing the same protocol for missed or incomplete miscarriage as
they do for abortion.511 Not only does this benefit women who
are experiencing a missed or incomplete miscarriage, but it
would also help to reduce mifepristone’s stigma. Pharmacists,
for instance, would not know whether women picking up a
prescription for mifepristone were using it for an abortion or for
a miscarriage, making it more difficult for them to object to
filling the prescription based on their conscience. This benefit
would exist across the country—even in abortion-restrictive
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states—as state laws limiting the provision of mifepristone are
often tied to abortion, not mifepristone specifically. As a result,
state laws would not limit mifepristone’s use outside of the
abortion context.
Removing the mifepristone REMS would radically change
abortion care in parts of the United States. Already, the FDA’s
decision to remove the in-person dispensing requirement
means that patients will no longer need to travel long distances
to clinics for early abortion, nor will they need to deal with the
harassment of protesters. Patients will be able to terminate an
early pregnancy at home, entirely through telemedicine. If the
FDA removed the rest of the unnecessary and burdensome
requirements, more providers would offer early abortion care,
and there will be less of an incentive for patients to rely on selfmanaged abortion to end a pregnancy. Mifepristone could be
used for a variety of obstetric uses, making it harder to politicize. However, in other parts of the country, access to legal
abortion will not improve; instead, state legislatures will continue to chip away at abortion rights—banning it completely if
the Supreme Court allows. Self-managed, illegal abortion will
likely become the norm in those states, which will be difficult to
regulate and police. Though the best evidence suggests that
self-managed abortion is safe, there are legal risks, and many
women would likely prefer to have a doctor oversee their
abortion.
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Medication abortion is an effective and safe way to end a
pregnancy in the first ten weeks. Nevertheless, the FDA has
dramatically limited its distribution by imposing a REMS—a
tool intended to protect the public from particularly risky
drugs. The REMS has segregated medication abortion outside
of traditional healthcare settings and into abortion and family
planning clinics. Before December 2021, the REMS also
banned remote abortion through telehealth, dramatically reducing access to abortion across the country.
Removing the REMS could represent the largest increase in
abortion access in decades, at least in the states that have not
passed state laws that limit access to medication abortion. Patients in those states will be able to receive abortion care entirely from the comfort of their own homes at lower cost
through telemedicine, never having to face the harassment associated with abortion clinics. More providers will be able to
provide early abortion care—and do so anonymously without
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threats of harassment and violence. None of these benefits will
be felt by those in states that continue to limit medication
abortion, and as a result, the FDA’s decision to remove or modify the mifepristone REMS, as it began to do in December, will
accelerate the trend toward polarization in abortion regulations
across the United States. This trend will only increase if Roe v.
Wade is limited or overturned as some states will outlaw abortion entirely, while patients in the remaining states will continue to experience the benefits associated with easier access to
medication abortion.
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